<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Neil S Seligman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brian J Cleary, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vincenzo Berghella, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Aaron B Caughey, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew J Saxon, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H16284319"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">Methadone</a> and <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> are used for pharmacotherapy of opioid use disorder (OUD) and medically assisted withdrawal, along with appropriate social and medical services. The comparative advantages and disadvantages of methadone versus buprenorphine pharmacotherapy of OUD are shown in the table  (<a class="graphic graphic_table graphicRef87713" href="/z/d/graphic/87713.html" rel="external">table 1</a>). </p><p>This topic will discuss administration and outcomes of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> and <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> for pharmacotherapy of OUD during pregnancy and postpartum. The use of pharmacotherapy versus medically-assisted withdrawal, choice of drug for pharmacotherapy, candidates for this therapy, maternal and fetal evaluation, labor and delivery management, and postpartum pain control are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/4790.html" rel="external">"Opioid use disorder: Overview of treatment during pregnancy"</a>.) </p><p class="headingAnchor" id="H999923979"><span class="h1">METHADONE PHARMACOTHERAPY</span></p><p class="headingAnchor" id="H1995379388"><span class="h2">Provider</span><span class="headingEndMark"> — </span>Regulations regarding provision of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> for OUD vary by state and/or country [<a href="#rid1">1</a>]. The provider should be aware of all opioid prescribing laws applicable in their area. </p><p>Successful pharmacotherapy of OUD depends upon a comprehensive, multidisciplinary, coordinated approach to care [<a href="#rid2">2,3</a>]. <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">Methadone</a> treatment centers usually offer individual and group counseling, and some may provide psychiatric and social services. A few, unique programs also offer health/parenting education and prenatal care.</p><p class="headingAnchor" id="H2929056591"><span class="h2">Pharmacology</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">Methadone</a> is a synthetic long-acting opioid agonist that binds to and occupies mu-opioid receptors, thus preventing withdrawal symptoms for 24 hours or longer, reducing craving for opioids, and, by maintaining high levels of opioid tolerance, reducing the euphoric effects of subsequent nonprescription opioid use.</p><p>It is available as an oral solution, tablet, and injectable solution. The oral solution is used for observed ingestion; the oral solution or tablets are used for take-home doses; the injectable solution is not used for pharmacotherapy of OUD [<a href="#rid4">4</a>]. It is advisable to avoid switching dosage forms, when possible, because withdrawal symptoms sometimes occur when a patient is switched to a different form [<a href="#rid5">5</a>]. </p><p>The half-life of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> falls substantially during pregnancy, from an average of 22 to 24 hours in nonpregnant individuals to 8.1 hours in pregnancy, due to changes in pharmacokinetics related to pregnancy [<a href="#rid6">6,7</a>]. Methadone metabolism is consistently accelerated in pregnancy due to significantly increased CYP3A4 expression by a variety of organs, including liver, intestine, and placenta [<a href="#rid6">6,8,9</a>]. Significant genetic diversity in the enzymes that metabolize methadone (CYP3A4, 2D6) result in different individual metabolic rates, and absorption is variable in pregnancy [<a href="#rid10">10</a>]. Metabolism generally increases with advancing gestational age [<a href="#rid11">11-16</a>]; therefore, higher doses or split dosing may be required to maintain therapeutic effects as pregnancy progresses.</p><p>Cord blood <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> levels correlate with maternal dose and gestational age, as methadone crosses the placenta in greater amounts in late pregnancy [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H978811503"><span class="h2">Initial dosing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to start</strong> – For pregnant patients desiring <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> pharmacotherapy, the drug should be initiated as early in gestation as possible to get the most maternal, obstetric, and neonatal benefit. For example, some studies have reported that earlier initiation of methadone was associated with improvements in perinatal outcome (eg, longer gestation, greater birth weight) [<a href="#rid17">17-20</a>]. In addition, in a study of 632 pregnant patients with OUD receiving treatment with MOUD, the risk of nonfatal overdose was inversely proportional to treatment duration [<a href="#rid21">21</a>]. </p><p></p><p class="bulletIndent1">In patients with a clear diagnosis of OUD  (<a class="graphic graphic_table graphicRef50295" href="/z/d/graphic/50295.html" rel="external">table 2</a>), there is no requirement that they show signs and symptoms of withdrawal before <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> can be initiated. Signs and symptoms typically appear four to six hours after the last dose of short-acting opioids, peak at one to three days (onset of and peak symptoms may occur later after long-acting opioids) [<a href="#rid22">22</a>], and include one or more of the signs/symptoms in the table  (<a class="graphic graphic_table graphicRef78130" href="/z/d/graphic/78130.html" rel="external">table 3</a>). The severity of each symptom depends on the individual's tolerance to opioids, the continued presence of opioid in the serum and end organs, and the duration of time over which withdrawal has occurred. Withdrawal symptoms generally subside after five to seven days [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/306.html" rel="external">"Opioid withdrawal in the emergency setting", section on 'Clinical features of opioid withdrawal'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Where to start</strong> – The optimum setting for initiation of therapy has not been evaluated in the pregnant population. We suggest hospitalization during initiation of treatment because of the potential for serious adverse events, such as overdose and adverse drug interactions. Hospitalization also facilitates daily fetal assessment (fetal heart rate or nonstress test depending on gestational age), which we perform in inpatients until the patient is stabilized (ie, when <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> occupies a sufficient number of opioid receptors to prevent withdrawal). This is also an ideal time for assessment by a social worker and case manager and for initiation of prenatal care. However, some authorities believe hospitalization is not necessary at initiation of therapy. </p><p></p><p class="bulletIndent1">It is important to emphasize that <strong>the approach described below applies to patients who are hospitalized while initiating </strong><a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>; initiation and titration of methadone in the outpatient setting must be guided by a different protocol. The dose adjustment recommended below should only be done in the inpatient setting as the upward titration described is too rapid to be safe for all patients in an outpatient setting, where the dose is typically increased no more frequently than every three to five days. Detailed information on dosing in the outpatient setting is available separately. (See  <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management"</a>.)</p><p></p><p class="headingAnchor" id="H3832997961"><span class="h3">Starting dose in hospitalized patients</span><span class="headingEndMark"> — </span>In most symptomatic patients, we begin therapy with a single oral dose of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> 20 to 30 mg [<a href="#rid11">11,24-28</a>]. After this dose, incremental doses of 5 to 10 mg are provided every three to six hours as needed to treat withdrawal symptoms  (<a class="graphic graphic_table graphicRef78130" href="/z/d/graphic/78130.html" rel="external">table 3</a>) [<a href="#rid24">24</a>]. In outpatients, United States Federal Regulations limit the initial dose to a maximum of 30 mg and the total first day dose to a maximum of 40 mg if withdrawal symptoms are not fully suppressed by the initial dose, but these restrictions do not apply to patients being treated in the hospital setting. Initiation and titration protocols avoid accumulation and overdose; however, some patients may benefit from more rapid titration. For example, patients who are using nonprescribed <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> often have extremely high tolerance and may need rapid titration of methadone to suppress withdrawal symptoms while being carefully monitored for respiratory depression. </p><p>For patients with no or only mild symptoms of withdrawal, an alternative approach is to begin with a low initial dose of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> 10 mg and provide incremental doses of 5 to 10 mg every four to six hours as needed for withdrawal symptoms on the first day of therapy. Mild symptoms of withdrawal can sometimes be managed adequately with counseling, supportive care, and/or <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a> 0.1 mg orally every four to six hours rather than with incremental doses of methadone.</p><p>Clinical observation and a structured instrument with a standardized scoring system (eg, Clinical Opiate Withdrawal Scale  (<a class="graphic graphic_table graphicRef106994" href="/z/d/graphic/106994.html" rel="external">table 4</a>)) can be used to assess the progress and severity of withdrawal. (See  <a class="medical medical_review" href="/z/d/html/7808.html" rel="external">"Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder", section on 'Monitoring'</a>.)</p><p class="headingAnchor" id="H1130666358"><span class="h3">Dose adjustments in hospitalized patients after the first day of treatment</span><span class="headingEndMark"> — </span>On the second day of hospital treatment, the total dose of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> administered over the previous 24 hours is provided as the new morning dose. Patients who initially presented with no or only mild symptoms and were given a low initial dose (10 mg) are provided no less than 30 mg on the second day. Incremental doses are provided as needed.</p><p>Daily increments to the morning dose are made until no additional incremental doses are needed to prevent signs and symptoms of withdrawal for at least 24 hours. This is the "stabilization dose" and is achieved when <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> occupies enough opioid receptors to prevent withdrawal [<a href="#rid29">29</a>]. Stabilization may take a week or more, and further adjustments over time may be needed.</p><p class="headingAnchor" id="H1940725538"><span class="h2">Maintenance dosing after initial stabilization</span><span class="headingEndMark"> — </span>Once the initial stabilization dose has been achieved, the patient is discharged and further dosing adjustments are made at an outpatient treatment center. The dose is not increased for several days even if symptoms occur; we usually wait at least 72 hours before considering an increase in dose [<a href="#rid30">30</a>]. After this 72-hour period, we increase the <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> dose in 5 to 10 mg increments per week, when indicated based on clinical evaluation, to maintain the lowest dose that controls withdrawal symptoms and minimizes cravings. Common discomforts of pregnancy such as nausea, vomiting, and low back pain are similar to some opioid withdrawal symptoms; this possibility should be considered before increasing the daily methadone dose in symptomatic patients [<a href="#rid31">31</a>]. The average patient will require three medication dose increases during the course of pregnancy because of increased metabolism related to the pregnant state [<a href="#rid32">32</a>]. (See <a class="local">'Pharmacology'</a> above.)</p><p>In our experience, the average <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> dose is approximately 120 mg per day. The optimal dose in pregnancy is controversial. The rationale for high-dose therapy is to reach a level sufficiently high that additional doses of nonprescription opioids do not result in euphoria [<a href="#rid26">26,30</a>]. Research from the National Institute on Drug Abuse indicates that methadone doses less than 60 mg are ineffective since they are less likely to prevent drug-seeking behavior. Pregnant patients appear to do better on higher (80 to 120 mg/day) rather than lower methadone doses [<a href="#rid33">33</a>]; doses at these levels are not overly sedating because tolerance develops [<a href="#rid30">30</a>]. Pharmacokinetic changes in methadone metabolism during pregnancy also play a role in the need for high doses. Using pharmacokinetic modeling, at a dose of 90 mg daily, 75 percent of (R-) and 94 percent of (S-) methadone trough levels were below the lower therapeutic window [<a href="#rid34">34</a>]. </p><p>Awareness of the role of bias in treatment outcomes is particularly important in the OUD population. One study demonstrated that pregnant patients who self-identified as Black or Hispanic received 67 percent of the dose of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> that white patients received at delivery (mean 105.8 mg versus 144.9 mg) [<a href="#rid35">35</a>]. Use of standardized, objective treatment guidelines may help reduce the disparities in healthcare experienced by patients of color.</p><p class="headingAnchor" id="H2052196263"><span class="h3">Role of twice-daily maintenance dosing</span><span class="headingEndMark"> — </span>Twice-daily dosing at 12-hour intervals (or rarely, three times daily at 8-hour intervals) results in more sustained plasma levels, fewer withdrawal symptoms, and less nonprescription opioid use than a single high <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> dose [<a href="#rid7">7,36</a>]. Another advantage of split dosing is that it does not suppress fetal movement and breathing as much as single dosing [<a href="#rid37">37,38</a>]. </p><p>However, split dosing is not possible for all patients because it requires take-home doses. In the US, federal and state regulations list criteria for patients who may have doses of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> to take home. Eligibility for take-home doses is usually based on adherence to program requirements for counseling and abstinence from nonprescription opioids and other prescription medication misuse (based on urine toxicology testing), as well as absence of recent criminal activity and capacity to store the take-home doses safely in the home environment.</p><p class="headingAnchor" id="H887150966"><span class="h2">Management of a missed dose</span><span class="headingEndMark"> — </span>If a patient misses a <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> dose, and this is confirmed with the opioid treatment program, they can resume therapy at the same dose if they have not missed more than three daily doses; after three days of missed doses, they would need restabilization. </p><p>If the missed dose cannot be confirmed, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> should not be provided. The patient should be admitted and assessed for withdrawal using the Clinical Opiate Withdrawal Scale  (<a class="graphic graphic_table graphicRef106994" href="/z/d/graphic/106994.html" rel="external">table 4</a>) [<a href="#rid39">39</a>]. If they are demonstrating signs or symptoms of withdrawal, methadone can be provided in incremental doses up to 50 percent of the reported maintenance dose until additional management can be coordinated with their opioid treatment program.</p><p>There is no specific requirement for fetal monitoring due to a missed dose in the absence of standard obstetric indications for fetal surveillance, though some centers routinely obtain a nonstress test or biophysical profile on all patients presenting to the labor and delivery triage unit with pregnancies at or beyond the lower limit of viability.</p><p class="headingAnchor" id="H2522263968"><span class="h2">Role of urine drug testing</span><span class="headingEndMark"> — </span>After the initial urine drug screening test (UDS) on initiation of care, serial UDS are performed to monitor for continued nonprescription opioid use. Ideally, UDS is performed at weekly visits; in the United States, federal regulations require UDS with a minimum of eight urine tests per year of treatment [<a href="#rid40">40</a>]. UDS is also suggested on admission to the hospital whether for giving birth or other reasons (especially complications possibly associated with nonprescription opioid use [eg, abruption]) if the results will impact maternal or neonatal care. A single positive UDS rarely would lead to discontinuation of medication-assisted treatment. The American Society of Addiction Medicine (ASAM) provides guidelines on the appropriate use of drug testing [<a href="#rid41">41</a>]. Their recommendations are available in multiple forms including an online pocket guide and mobile app [<a href="#rid42">42</a>]. </p><p>Consent for UDS is not explicitly required; however, a UDS has the same risk of informational harm as other tests that require consent (eg, HIV testing, genetic testing). We agree with the American College of Obstetricians and Gynecologists (ACOG) that consent for UDS should be obtained when possible and in compliance with state laws [<a href="#rid43">43</a>].</p><p>One- to two-thirds of patients enrolled in <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> programs continue to use nonprescription opioids and/or misuse other prescription medications or alcohol during pregnancy [<a href="#rid44">44</a>]. Detecting continued polysubstance use is important because it is an indication for additional psychosocial intervention and possibly an increase in methadone dose. In addition, continued polysubstance use may lessen some of the benefits of methadone therapy and increase the incidence and severity of neonatal abstinence syndrome (NAS) [<a href="#rid18">18,45</a>]. For example, use of both benzodiazepines and methadone has been associated with lower birth weight, increased incidence and severity of NAS, and increased risk of maternal respiratory difficulties, coma, or death [<a href="#rid27">27,46,47</a>]. If benzodiazepines are being used, they should be carefully tapered. (See  <a class="medical medical_review" href="/z/d/html/88407.html" rel="external">"Benzodiazepine use disorder", section on 'Medically supervised taper'</a>.)</p><p>UDS vary with respect to the drugs included in the testing panel. Most panels include naturally occurring opioids and their metabolites, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, cocaine, benzodiazepines, barbiturates, amphetamines, and phencyclidine. Testing for synthetic opioids (eg, <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a>, <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>) and <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> may need to be ordered separately. However, an increasing number of commercially available panels test for more substances, including some synthetic opioids (eg, oxycodone, buprenorphine). Providers should be aware of the specific drug tests available to them locally. A detailed discussion of urine drug screening and testing, including interpretation, limitations, validity, and reliability, can be found separately. (See  <a class="medical medical_review" href="/z/d/html/13846.html" rel="external">"Testing for drugs of abuse (DOAs)"</a>.)</p><p class="headingAnchor" id="H2573764311"><span class="h2">When to check methadone levels</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">Methadone</a> levels are unnecessary in asymptomatic patients. Determination of a therapeutic dose is based on patient response, which can vary widely among patients [<a href="#rid48">48</a>]. </p><p>We recommend checking a <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> serum trough level in:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who remain symptomatic despite increases in <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> dose </p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are excessively sedated two to four hours after dose administration but develop craving or withdrawal symptoms before the next dose is due </p><p></p><p>However, a single <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> trough level can be difficult to interpret, the number of trough levels for reliable interpretation is unknown, and the turnaround time for the test is typically &gt;7 days, which makes it somewhat impractical. Trough levels should be drawn 24 hours after methadone dose administration [<a href="#rid48">48</a>]. There is no defined therapeutic window, but a methadone trough level of 300 to 400 ng/mL in nonpregnant individuals suggests an adequate total methadone dose and reduced likelihood of heroin use [<a href="#rid49">49</a>] and observations in pregnant patients are consistent with this finding. In a prospective study that evaluated serum trough levels in a cohort of pregnant patients, asymptomatic patients had mean trough levels of 300±160 ng/mL, which was significantly higher than mean trough levels in symptomatic patients (180±110 ng/mL) [<a href="#rid50">50</a>]. </p><p>If the trough level is &lt;300 ng/mL, management should be guided by symptoms. Withdrawal symptoms in patients with a low trough level suggest that an increased dose may be needed. Excessive sedation with a low trough level often indicates ongoing nonprescription opioid use. </p><p>Rapid metabolism of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> is possible. Rapid metabolizers tend to have a peak to trough ratio &gt;2:1, although peak to trough ratios are not measured clinically. These patients may benefit from split dosing rather than an increase in dose. (See <a class="local">'Role of twice-daily maintenance dosing'</a> above.)</p><p>Note: Drug levels are not useful during induction of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> because a steady state has not been achieved yet.</p><p class="headingAnchor" id="H3435233693"><span class="h2">Side effects</span></p><p class="bulletIndent1"><span class="glyph">●</span>Side effects of chronic <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> therapy include constipation, mild drowsiness, excessive sweating, and peripheral edema. (See  <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic use of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> and other opioid agonists may result in an increased sensitivity to pain, which may develop within a month of initiating chronic opioid therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">Methadone</a> can prolong the QT interval and cause torsades de pointes and sudden death. Higher methadone doses increase the risk for these events [<a href="#rid51">51</a>]. The confounding influence of other drugs (eg, <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>, <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a>, <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a>, <a class="drug drug_general" data-topicid="9820" href="/z/d/drug information/9820.html" rel="external">promethazine</a>, and selective serotonin reuptake inhibitors), a prolonged QT interval at baseline, and hypokalemia also contribute to this risk. An electrocardiogram is recommended before initiation of methadone for patients with significant risk factors [<a href="#rid48">48</a>]. This complication of methadone therapy and approaches to identify patients at high arrhythmic risk are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H3096352034"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span>Clinicians should be aware that drug-drug interactions may occur with several common medications and may require the patient's daily <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> dose to be adjusted to prevent complications from such drug-drug interactions. A number of the drug interactions are based on metabolism by the cytochrome P450 isoenzyme system, specifically 3A4. Selected interactions are discussed below and more information is available in the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">Magnesium sulfate</a> – Though there may be a theoretical risk of additive central nervous system and/or cardiorespiratory depressive effects with combined use of opioids and high doses of magnesium sulfate (as used for prevention of eclamptic seizures or for fetal/neonatal neuroprotection), we have neither observed nor read case reports of such adverse drug interactions and do not alter dosing in patients receiving both drugs during labor. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opioid antagonists</strong> – <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">Naloxone</a> and other narcotic antagonists may precipitate withdrawal in both the pregnant patient and fetus [<a href="#rid6">6,11,52</a>]. Mixed agonists/antagonist analgesics that are sometimes considered for labor analgesia (eg, <a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">nalbuphine</a>, <a class="drug drug_general" data-topicid="9179" href="/z/d/drug information/9179.html" rel="external">butorphanol</a>, <a class="drug drug_general" data-topicid="9753" href="/z/d/drug information/9753.html" rel="external">pentazocine</a>) should be avoided. (See  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults", section on 'Basic measures and antidotal therapy'</a> and  <a class="medical medical_review" href="/z/d/html/99945.html" rel="external">"Prevention of lethal opioid overdose in the community"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> – The antituberculosis drug rifampin induces CYP3A4 and alters P-glycoprotein binding [<a href="#rid52">52,53</a>], which reduces the plasma concentrations of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> and may lead to opioid withdrawal. Therefore, higher doses of methadone may be required in pregnant patients who are taking rifampin [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiseizure medications</strong> – The antiseizure medications <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> and <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> induce metabolism of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>. In one study, nonpregnant, methadone-maintained individuals experienced withdrawal symptoms within three to four days of starting phenytoin [<a href="#rid54">54</a>]; a similar response is likely in pregnant patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiretroviral drugs</strong> – <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">Methadone</a> increases blood levels of <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a> and may require a 50 percent reduction of the usual dose [<a href="#rid6">6</a>]. Methadone can also decrease concentrations of <a class="drug drug_general" data-topicid="9351" href="/z/d/drug information/9351.html" rel="external">didanosine</a> and <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">stavudine</a>. <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">Darunavir</a>, <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a>, <a class="drug drug_general" data-topicid="9685" href="/z/d/drug information/9685.html" rel="external">nelfinavir</a>, <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a>, and lopinavir/<a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a> all have the potential to reduce serum methadone concentrations, which could result in methadone withdrawal symptoms and necessitate a methadone dose increase.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – The H2 antagonist <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">cimetidine</a> and the antifungal medication <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a> increase <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> levels [<a href="#rid28">28</a>]. </p><p></p><p class="headingAnchor" id="H1540005098"><span class="h2">Intrapartum and postpartum methadone dosing</span><span class="headingEndMark"> — </span>The patient's usual oral <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> dose is continued intrapartum (during labor or before scheduled cesarean birth) and postpartum to prevent withdrawal. Intrapartum, some clinicians divide the daily methadone dose into three doses administered every eight hours. (See  <a class="medical medical_review" href="/z/d/html/130304.html" rel="external">"Obstetric anesthesia for patients with opioid use disorder or opioid tolerance", section on 'Continue baseline opioid'</a>.)</p><p>Although postpartum over-sedation is a theoretic concern since <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> levels may increase as plasma volume and hepatic clearance return to the prepregnant state, we have not observed any cases of oversedation. In a study of 101 methadone-maintained pregnant patients followed for 12 weeks after giving birth, the mean dose change was -3.7 mg (-6.3 to -1.1 mg), 50 percent of patients had either the same or higher methadone doses postpartum, and 5.6 over-sedation events occurred per 10,000 dosing days [<a href="#rid55">55</a>]. Several other studies confirm that most patients will not achieve a significant dose reduction after delivery. The common perception that patients can resume their prepregnancy opioid dose once the metabolic changes of pregnancy resolve postpartum may not be appropriate for feasible [<a href="#rid56">56-58</a>].</p><p>Continuing MOUD after discharge is important to support abstinence from other opioids and retention in treatment of OUD. (See  <a class="medical medical_review" href="/z/d/html/4790.html" rel="external">"Opioid use disorder: Overview of treatment during pregnancy", section on 'Continue MOUD'</a>.)</p><p class="headingAnchor" id="H3581390165"><span class="h2">Breastfeeding</span><span class="headingEndMark"> — </span>Breastfeeding should be encouraged in patients who are stable on <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> and not using nonprescription opioids or misusing other prescription drugs, unless other contraindications exist [<a href="#rid59">59</a>]. This recommendation is supported by guidelines from ACOG and the Academy of Breastfeeding Medicine [<a href="#rid60">60</a>] and apply to patients who are enrolled in a methadone program on any dose of methadone. Some of the benefits include improved maternal-infant attachment and favorable effects on NAS [<a href="#rid61">61-64</a>]. It is not clear whether the favorable effects of breastfeeding on NAS are related to breast milk, skin-to-skin contact, or the act of breastfeeding since the amount of methadone in breast milk is small [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/z/d/html/5013.html" rel="external">"Infant benefits of breastfeeding"</a> and  <a class="medical medical_review" href="/z/d/html/5022.html" rel="external">"Maternal and economic benefits of breastfeeding"</a>.)</p><p>Neonatal plasma concentrations of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> are not related to maternal methadone dose [<a href="#rid62">62</a>]. The estimated dose of methadone in breast milk is 1 to 3 percent of the maternal weight-adjusted dose [<a href="#rid66">66</a>]. Infants who were exposed to methadone in utero remain at risk for withdrawal symptoms even while being breastfed by mothers receiving methadone [<a href="#rid67">67</a>]. In very rare cases, infants exposed to methadone in breast milk have experienced serious side effects including severe respiratory depression, heart problems, and death [<a href="#rid68">68,69</a>]. </p><p class="headingAnchor" id="H1984194855"><span class="h3">Weaning</span><span class="headingEndMark"> — </span>In mothers receiving <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, there is no evidence that the infant is at risk for NAS during gradual reduction of breastfeeding; however, rare reports have described occurrence of NAS when breastfeeding was abruptly discontinued [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes", section on 'Deciding on method'</a>.)</p><p class="headingAnchor" id="H1094047647"><span class="h2">Pregnancy outcome</span><span class="headingEndMark"> — </span>There is ongoing debate about whether intrauterine exposure to <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> results in long-lasting effects on offspring. The available data, discussed below, are generally reassuring. According to the Substance Abuse and Mental Health Services Administration, the benefits of pharmacotherapy for OUD during pregnancy outweigh the risks of untreated OUD [<a href="#rid71">71</a>]. </p><p class="headingAnchor" id="H1870249881"><span class="h3">Neonatal abstinence syndrome</span><span class="headingEndMark"> — </span>Newborns who withdraw from opioids present with a well-recognized constellation of signs and symptoms known as neonatal abstinence syndrome (NAS). Withdrawal from <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> usually occurs 48 to 72 hours after birth but rarely may be delayed by up to a month [<a href="#rid72">72,73</a>]. The relationship between maternal methadone dose and neonatal withdrawal is controversial and limited by several study design factors. A 2010 meta-analysis concluded that the body of evidence suggests no correlation between methadone dose and severity of neonatal withdrawal at clinically relevant doses [<a href="#rid74">74</a>]. However, a more contemporary single-center retrospective study of 574 methadone-exposed infants, which included a broader range of doses (5 to 610 mg), found a positive correlation between methadone dose and severity of NAS [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes"</a> and  <a class="medical medical_review" href="/z/d/html/5010.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Clinical features and diagnosis"</a>.)</p><p>When recognized and managed appropriately, there are no proven long-term sequelae of NAS; however, treatment often requires a lengthy neonatal intensive care unit admission (median length of stay from 13 to 19 days) and results in significant health care costs (totaling USD $1.5 billion in aggregate costs or USD $66,700 per infant with NAS [<a href="#rid76">76,77</a>]). Frequently overlooked are the significant maternal psychologic stress from feelings of guilt and sadness and delayed maternal-fetal bonding when the infant is in an intensive care unit rather than rooming in or at home.</p><p>The clinical manifestations and management of neonatal withdrawal are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes"</a>.)</p><p class="headingAnchor" id="H3686382185"><span class="h3">Risk of congenital anomalies</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">Methadone</a> is not clearly associated with any structural fetal anomalies [<a href="#rid71">71</a>]. In a 2016 systematic review comparing methadone versus <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> treatment of pregnant patients with OUD (one randomized trial [131 neonates] and four observational studies [933 neonates]), there was no significant difference in risk of congenital anomalies between the two treatments, and the overall risk of anomalies was similar to that in the general obstetric population [<a href="#rid78">78</a>]. </p><p>While some individual studies have described congenital anomalies, there is no clear pattern of anomalies [<a href="#rid79">79</a>]. Additionally, the available information is complicated by multiple confounders including maternal use of nonprescription opioids, use/misuse of other prescription medications, other illicit drug use, high smoking rates, poor nutrition, increased prevalence of infection, poor engagement with antenatal care, and complicated psychosocial circumstances. Other methodologic issues include lack of an appropriate control group, failure to provide adequate details about timing of exposure, and poor characterization of anomalies. Most studies used a cross-sectional study design, which cannot prove causation.</p><p>Several studies have reported an association between <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> exposure and Pierre Robin sequence (PRS) [<a href="#rid80">80-82</a>]. The largest of these used data from 12 European Surveillance of Congenital Anomalies (EUROCAT) registries covering nearly four million births [<a href="#rid81">81</a>]. There was an association between methadone exposure and PRS (odds ratio 15.5; 95% CI 6.1-33.3); however, the study was unable to show causation due to potential confounding factors such as alcohol use and smoking, which are similarly associated with PRS. Regardless, the prevalence of PRS is very low (&lt;1/10,000 births), so the possible absolute increase in PRS with methadone exposure is small and should be balanced against the risk of untreated OUD during pregnancy, which has well-described adverse consequences.</p><p class="headingAnchor" id="H391314287"><span class="h3">Risk of other fetal and neonatal effects</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid</strong> — Enlargement of the fetal thyroid has been reported in methadone-exposed infants, possibly due to changes in monoamine neurotransmitter systems [<a href="#rid83">83</a>]. The functional significance of this enlargement is unclear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prolonged QTc</strong> — QTc intervals &gt;450 milliseconds have been reported in 15 to 19 percent of methadone-exposed neonates. All resolved by seven days without cardiac events [<a href="#rid51">51,84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Visual development</strong> — Several studies have suggested that prenatal exposure to <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> may result in abnormal visual development. In a systematic review of 12 studies that reported visual outcomes in offspring of patients prescribed methadone in pregnancy (275 methadone-exposed versus 128 unexposed), the prevalence of childhood strabismus and nystagmus in the methadone-exposed population was approximately 50 percent, which was higher than expected; differences in visual evoked potentials (VEPs) were also noted [<a href="#rid85">85</a>]. In one of the included studies, the majority (70 percent) of infants with prenatal exposure to methadone demonstrated some type of visual disturbance [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1">Most studies lacked sufficient information to adequately control for other prenatal exposures, thus limiting the ability to make any conclusion about causation. The prevalence of tobacco use among patients with OUD is &gt;90 percent. Like <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, prenatal exposure to tobacco and other illicit drugs (eg, cocaine, amphetamines) has also been associated with ophthalmic abnormalities [<a href="#rid87">87</a>]. Maternal smoking increases the risk for optic nerve hypoplasia and also results in a significantly thinner retinal nerve fiber layer [<a href="#rid88">88</a>]. Additionally, a study found that strabismus increased proportionally with the number of cigarettes smoked, reaching a relative risk of 1.9 (95% CI 1.57-2.30) at &gt;10 cigarettes/day [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1">The long-term significance of these findings is unclear. In at least one study, differences in VEPs in infants born to patients with OUD-prescribed <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> remained after adjusting for tobacco use [<a href="#rid86">86</a>]. In another study, the findings were transient: In 36-month old children, there was no difference in VEPs between children exposed to methadone and a group of unexposed children [<a href="#rid90">90</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Size and gestational age at birth</strong> — <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">Methadone</a> pharmacotherapy has been associated with an increased risk of adverse neonatal outcomes, such as preterm birth &lt;32 weeks of gestation, small for gestational age infants, low birth weight, decreased head circumference, and sequelae often associated with these outcomes: jaundice, thrombocytosis, and admission to a neonatal intensive care unit [<a href="#rid80">80,91</a>]. However, methadone pharmacotherapy appears to improve birth weight compared with patients using nonprescription opioids, even if not quite to the birth weights seen in the general population (mean difference -295 g). </p><p></p><p class="bulletIndent1">The association between in utero exposure to <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> and adverse outcome is somewhat explained by confounders such as race, body mass index, gestational weight gain, cigarette smoking, socioeconomic deprivation, maternal age, and parity [<a href="#rid80">80,92-95</a>]. Although some studies have reported that daily doses of 80 to 160 mg adversely affected fetal growth, these findings have not been consistent across studies and could have been due to confounders [<a href="#rid19">19,44,96,97</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sudden neonatal death</strong> — Opiates have been implicated as a cause of sudden infant death [<a href="#rid98">98</a>]. A retrospective study of sudden death demonstrated an unexpectedly high proportion of neonatal deaths in which there was a maternal history of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> use (31 percent of 32 neonatal deaths evaluated by autopsy) [<a href="#rid99">99</a>]. Many of these were also complicated by maternal nonprescription opioid use and misuse of other prescription drugs. Whether the deaths were related to methadone (possibly due to QT prolongation) or other factors (eg, exposure to parental smoking or unsafe sleeping practices) is unclear. </p><p></p><p class="bulletIndent1">While not all factors are easily addressed in the short term, unsafe sleep practices (8 of 32 cases) is an opportunity for harm reduction; patients should be educated about safe sleep before being discharged home, and the message should be reinforced at visits with a medical provider during the postpartum period. (See  <a class="medical medical_review" href="/z/d/html/6366.html" rel="external">"Sudden infant death syndrome: Risk factors and risk reduction strategies", section on 'Sleep position and environment'</a>.)</p><p></p><p class="headingAnchor" id="H3039384865"><span class="h3">Risk of adverse long-term consequences</span><span class="headingEndMark"> — </span>Determining the possible long-term consequences of in utero <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> exposure is complicated by a multitude of factors, including concomitant prenatal and postnatal exposures, medical factors, and sociodemographic factors, all of which have potential implications for neurodevelopmental outcome. Another limitation is the high rates of attrition (31 to 70 percent) in many studies [<a href="#rid85">85</a>]. While research attempts to adjust for these variables, confounding by other measurable or unmeasurable differences between groups limits conclusions that can be drawn about prenatal opioid exposure and long-term neurodevelopmental outcome [<a href="#rid100">100</a>]. Therefore, the clear benefits of treatment of OUD with maintenance agonists should be emphasized when counseling patients with OUD about treatment.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopment</strong> – Differences in motor performance, speech and language performance, cognitive performance, and behavior have all been reported in methadone-exposed infants and children. In a 2019 meta-analysis<strong> </strong>of childhood neurodevelopment after prescription of maintenance <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> for opioid dependency in pregnancy, compared with unexposed infants, methadone exposure was associated with a lower Mental Development Index (MDI; weighted mean difference [WMD] -4.43, 95% CI -7.24 to -1.63) and lower Psychomotor Development Index (PDI; WMD -5.42, 95% CI -10.55 to -0.28) at age two years, but no differences were seen in studies reporting MDI and PDI at age six months [<a href="#rid85">85</a>]. The authors postulated that differences often appear as children grow older. Studies published subsequent to the meta-analysis have demonstrated similar results while controlling for confounding to the extent possible [<a href="#rid101">101,102</a>].</p><p></p><p class="bulletIndent1"><strong>Opioids (and opioid metabolites) freely cross the placenta</strong> – Opioid receptors are present in several fetal neurologic structures from a very early gestational age. Studies demonstrating that <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> may alter development of dopaminergic, cholinergic, and serotonergic systems; myelination; and the microstructure of major white matter tracts lend biologic plausibility to the concept that in utero exposure to methadone may have adverse long-term neurodevelopmental consequences [<a href="#rid103">103,104</a>]; however, this probably applies to most, if not all, opioids and is not specific to methadone. Findings from neuroimaging studies also have significant limitations due to failure to account for polysubstance abuse, smoking, nutritional deficiency, and other antenatal and early life exposures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hospitalization</strong> – In a registry study from the Czech Republic, hospitalization for infection, gastrointestinal, and skin diseases among children ages 0 to 3 years was higher among offspring of mothers in an opioid maintenance treatment program than those in the general population; in utero <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> exposure was associated with a higher risk of hospitalization and longer hospitalization than in utero <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> exposure [<a href="#rid105">105</a>]. Notably, in the Czech Republic, methadone is available at no cost while buprenorphine may be cost-prohibitive for many patients, which introduces bias based on ability to pay.</p><p></p><p class="headingAnchor" id="H16284373"><span class="h1">BUPRENORPHINE PHARMACOTHERAPY</span></p><p class="headingAnchor" id="H3296081887"><span class="h2">Provider</span><span class="headingEndMark"> — </span>In the United States, <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> can be dispensed by an opioid treatment program and can be prescribed by any provider who is licensed under state law and possesses a valid Drug Enforcement Administration (DEA) registration. In 2023 the Consolidated Appropriations Act removed the requirement of obtaining a federally required DATA waiver (X-Waiver). This allows clinicians with schedule III authority on their DEA registration to prescribe buprenorphine for opioid use disorder if permitted by applicable state law [<a href="#rid106">106</a>]. The limits on the number of patients a prescriber may treat for OUD with buprenorphine were also removed.</p><p>A <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.samhsa.gov%2Fmedication-assisted-treatment%2Ffind-treatment%2Ftreatment-practitioner-locator&amp;token=otLO7jb45H786cQmS%2FXOd9hz9dMyNAu5vA0THTSKDPFEBL7VVVV%2Br6wD%2FJsk7jhcAweKLcu5rOJzmTBQqrwtDi1dQ42Ihp7dri3gl7AedpA%3D&amp;TOPIC_ID=87238" target="_blank">directory of providers</a> licensed to prescribe <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> is available online. It is not a complete listing because clinicians can request not to be listed.</p><p>Pregnant patients may experience more difficulty compared with nonpregnant patients when attempting access treatment from <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> providers. This may be due to variability in insurances accepted, high out-of-pocket costs, and the provider's comfort level treating pregnant individuals [<a href="#rid107">107</a>].</p><p>As with <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, successful pharmacotherapy depends upon a comprehensive, multidisciplinary, coordinated approach to care [<a href="#rid2">2,3</a>]. In contrast to methadone, which is typically administered at a comprehensive treatment center (ie, availability of pharmacotherapy along with social work and psychiatry), <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> is typically prescribed in the office of the credentialed clinician, unless the patient is admitted for opioid withdrawal and/or to coordinate outpatient treatment. If prenatal care is not available onsite at the office, then these services will need to be arranged separately [<a href="#rid26">26,30,108</a>]. </p><p class="headingAnchor" id="H16284340"><span class="h2">Pharmacology</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">Buprenorphine</a> acts as a partial agonist at the mu-opioid receptor and has a prolonged duration of action due to its high affinity for the receptor. It is also an antagonist at the kappa opioid receptor. Pharmacologic effects are similar to full opioid agonists (eg, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>), but with a "ceiling effect" at high doses across a range of pharmacodynamic measures [<a href="#rid109">109</a>]. This lowers the potential for adverse effects from overdose (eg, respiratory depression), but could also explain why there is greater treatment retention with methadone, especially compared with certain buprenorphine doses/dosing regimens.</p><p><a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">Buprenorphine</a> suppresses withdrawal for 24 to 48 hours; typical dosing for OUD is every 24 hours [<a href="#rid110">110,111</a>]. Peak plasma levels occur at approximately 90 minutes and increase linearly with increasing dose. The drug is highly lipophilic, 96 percent bound to plasma proteins, and metabolized by the liver with an active metabolite, norbuprenorphine [<a href="#rid111">111</a>]. It is primarily metabolized by the cytochrome P450 enzyme pathway.</p><p>Lower maximum plasma <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> concentrations and total 24-hour plasma levels have been demonstrated during pregnancy compared with the postpartum period [<a href="#rid112">112</a>]. In one study, some patients with OUD excreted a higher percentage of their daily buprenorphine dose during pregnancy than postpartum, indicating possible enhanced renal elimination antenatally [<a href="#rid113">113</a>]. Most of the study participants were prescribed a higher buprenorphine dose as pregnancy progressed.</p><p><a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">Buprenorphine</a> and its pharmacologically active metabolites cross the placenta [<a href="#rid114">114,115</a>]. In a study of patients with OUD receiving maintenance doses of buprenorphine, mean cord/maternal ratios for buprenorphine and norbuprenorphine were 0.43 and 0.53, respectively [<a href="#rid115">115</a>]. Transplacental transfer and metabolism do not appear to differ significantly in preterm placentas [<a href="#rid116">116</a>].</p><p class="headingAnchor" id="H2654859388"><span class="h2">Formulations and administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">Buprenorphine</a> is available in a variety of forms and is available with and without <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>. In the United States, formulations approved by the US Food and Drug Administration include sublingual tablets, film, buccal film (form with naloxone no longer available), and implant. Sublingual, or buccal, formulations have significantly greater bioavailability compared with oral administration and are the most common formulation used during pregnancy.</p><p>Proper use of <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> films or tablets is important to ensure absorption; misuse may result in lower bioavailability and consequently lower peak concentrations/effect. Patients should be instructed to drink water to moisten the mouth before taking buprenorphine. Buprenorphine is placed under the tongue (left or right side) or inside the cheek depending on prescribed route of administration and kept in place until completely dissolved, which typically takes 30 minutes. Buprenorphine should not be chewed or swallowed. Eating, drinking, and/or smoking cigarettes should be avoided until the medication has fully dissolved. </p><p><a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">Buprenorphine</a> has been available as an implant (Probuphine) since 2016 and a monthly extended-release subcutaneous injection (Sublocade) since 2017. There are no adequate or well-controlled studies of these formulations in pregnant patients; however, the risks should be comparable to buprenorphine in other forms. The implant is an option for nonpregnant patients with sustained clinical stability on no more than 8 mg of buprenorphine. In patients who conceive while using an implant, we recommend not removing it; however, they should be closely monitored for symptoms as a higher dose of buprenorphine may be required during pregnancy and the dose of the implant cannot be changed [<a href="#rid117">117</a>]. The implant can be supplemented with sublingual buprenorphine in these cases.</p><p class="headingAnchor" id="H1921528762"><span class="h2">Initial and maintenance dosing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to start</strong> – Because it is a partial agonist at the mu-opioid receptor, initiation of <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> may lead to withdrawal symptoms in patients who have recently used opioids. To minimize this risk, it should be initiated when a patient begins to show objective, observable signs of moderate withdrawal  (<a class="graphic graphic_table graphicRef78130" href="/z/d/graphic/78130.html" rel="external">table 3</a>), usually six hours or longer after the last dose of a short-acting opioid, and potentially longer (24 hours to 48 hours) following the use of long-acting opioids [<a href="#rid118">118,119</a>], but before severe withdrawal symptoms occur. Alternatively, microdosing does not require patients to abstain from opioids. </p><p class="bulletIndent1">Bothersome mild withdrawal symptoms during this time can be treated with a variety of over-the-counter and prescription medications, such as <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> for aches, antacids for indigestion, <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> for diarrhea, and <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">hydroxyzine</a> or <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> for anxiety and restlessness [<a href="#rid119">119</a>]. Alternatively, <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a> can be prescribed. (See  <a class="medical medical_review" href="/z/d/html/306.html" rel="external">"Opioid withdrawal in the emergency setting", section on 'Management'</a> and <a class="local">'Starting dose in hospitalized patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial dosing</strong> – There is no consensus on the optimal method of induction of <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> during pregnancy [<a href="#rid118">118-120</a>]. Our approach for initial and subsequent dosing is the same as that in nonpregnant patients: A typical starting dose for buprenorphine is 2 to 4 mg given sublingually. After two hours of observation, if withdrawal symptoms remain, an additional 2 to 8 mg of buprenorphine can be administered. </p><p></p><p class="bulletIndent1">On the following day, the patient is given a single dose consisting of the total of the doses received the first day (up to 8 mg). Following observation for residual withdrawal symptoms, the dose may be increased in 4 mg increments, up to a maximum of 16 mg total during initial stabilization. Most patients will stabilize on 8 to 16 mg/day [<a href="#rid121">121</a>], so the dose should not be increased above 16 mg for several days to allow time to reach pharmacologic steady state. (See  <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Buprenorphine: Opioid agonist'</a>.) </p><p></p><p class="bulletIndent1">One study observed that <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> is cleared more extensively by pregnant than postpartum patients [<a href="#rid122">122</a>], and some authors have suggested three or four times daily dosing may be required in pregnancy to sustain plasma concentrations [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of low-dose initiation </strong>– Conventional <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> induction protocols may initiate precipitated withdrawal. This is of particular concern because of the increased prevalence of <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> use, which has been associated with a higher risk of precipitated withdrawal attributed to its specific pharmacologic properties (wide interindividual variability in elimination half-life, high affinity for the mu-opioid receptor, and lipophilicity leading to a large volume of distribution) [<a href="#rid42">42,123</a>]. Rather than waiting for moderate withdrawal, an alternative strategy is low-dose initiation ("microinduction" or "microdosing"), which uses small buprenorphine doses (as low as 150 mcg), slowly escalating the dose over the course of several days. </p><p></p><p class="bulletIndent2">Microdosing may be considered in patients who are unable to tolerate the opioid withdrawal associated with traditional induction, patients transitioning from <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> to <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a>, or patients using illicit <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> as they may experience greater withdrawal effects [<a href="#rid123">123</a>].</p><p></p><p class="bulletIndent2">Reports of this approach to treatment of OUD in pregnancy are limited but have reported good outcomes [<a href="#rid124">124-127</a>]. This method of induction should only be used by providers with adequate experience.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance dosing</strong> – Some authors have suggested that unlike <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, patients maintained on <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> typically do not require large dose adjustments during pregnancy [<a href="#rid118">118</a>]. However, data from three randomized trials [<a href="#rid128">128-130</a>] demonstrated the need for buprenorphine dose adjustments throughout pregnancy; the average increase was 3 mg [<a href="#rid120">120</a>]. Pharmacokinetic studies confirm increased CYP- and UGT-mediated metabolism providing physiologic evidence to support dose increases [<a href="#rid131">131</a>].</p><p></p><p class="headingAnchor" id="H3780742840"><span class="h3">Patients with hepatic or renal insufficiency</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatic dysfunction </strong>– <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">Buprenorphine</a> is primarily metabolized by the liver. Severe hepatic dysfunction is a contraindication to use. Lesser degrees of hepatic dysfunction may impair buprenorphine metabolism; in these patients, a reduction in dose or the frequency of administration may be necessary. </p><p></p><p class="bulletIndent1">Liver function tests are obtained at baseline, but waiting for the results should not delay treatment [<a href="#rid132">132</a>]. The tests should be repeated periodically during treatment. There is no evidence to guide the frequency of monitoring, but testing every six months is adequate for most patients. Prompt additional testing is indicated in those with signs/symptoms of hepatotoxicity (eg, fever, malaise, nausea/vomiting). </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">Buprenorphine</a> can cause significant elevations in aspartate aminotransferase and alanine aminotransferase [<a href="#rid133">133,134</a>]. In patients with laboratory evidence of hepatotoxicity (transaminase levels &gt;3- to 5-fold higher than normal), all possible causes of liver injury should be evaluated and consideration should be given to lowering the dose or discontinuing buprenorphine [<a href="#rid135">135</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal impairment</strong> – Some authors believe that <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> doses do not need to be adjusted in patients with renal impairment [<a href="#rid133">133,134</a>]; however, manufacturers suggest caution when dosing patients with severe renal impairment (creatinine clearance &lt;30 mL/min), or slow titration of doses until dose stabilization [<a href="#rid136">136-138</a>]. In clinical practice, buprenorphine is mainly metabolized in the liver and can be safely tolerated by patients with renal impairment; however, these patients should be monitored for symptoms and dose adjustments made based on clinical assessment.</p><p></p><p class="headingAnchor" id="H1527900194"><span class="h2">Management of a missed dose</span><span class="headingEndMark"> — </span>Patients may present to the labor and delivery unit requesting <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> because of a "lost" or "stolen" dose. In this case, efforts should be made to contact their prescriber to confirm dosing and follow-up. If the provider cannot be reached and assistance from a clinician with experience in this area is not available, the patient should be questioned to detect any suggestion of drug diversion or nonprescription opioid use and examined to assess for signs of intoxication/overdose or withdrawal (eg, using the Clinical Opiate Withdrawal Scale score), and urine should be sent for a toxicology screen. (See  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults", section on 'Clinical features of overdose'</a> and  <a class="medical medical_review" href="/z/d/html/7808.html" rel="external">"Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder"</a>.)</p><p>In the absence of evidence of other opioid use, a single missed dose of <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> can be replaced safely and the usual dose resumed. Prescription drug monitoring programs exist in every state except Missouri. Many will include recent prescriptions for controlled substances including buprenorphine, and the dose can often be confirmed this way. If a record of the dose is not available or there is any concern about the patient’s reliability, a 2 mg test dose can be given. If there is no evidence of sedation, then the patient's usual dose can be given two hours later. The patient should only be given a single dose of their usual dose and then referred to their personal buprenorphine provider for further management. </p><p>A brief period of maternal observation may be considered before discharging the patient. There is no requirement for fetal assessment in the absence of other indications, though some centers routinely obtain a nonstress test or biophysical profile on all patients presenting to labor and delivery unit triage who are at or beyond the lower limit of viability.</p><p class="headingAnchor" id="H2859062156"><span class="h2">Role of urine drug testing</span><span class="headingEndMark"> — </span>Urine drug testing for patients on <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> is performed as clinically appropriate, in contrast to those on <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> who are supposed to have at least eight urine drug screening tests (UDS) per year [<a href="#rid40">40</a>]. The frequency of UDS to monitor adherence to therapy and continued nonprescription opioid use varies by phase of treatment. Early in treatment, UDS may be performed every one to two weeks and then at least monthly during maintenance treatment.</p><p>A specialized assay can be ordered to detect <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> since it is often not detected by standard UDS, which identifies naturally occurring opiates and their metabolites. However, an increasing number of UDS are able to detect buprenorphine, so providers should be familiar with the tests available at their location.</p><p class="headingAnchor" id="H3909248084"><span class="h2">When to check buprenorphine levels</span><span class="headingEndMark"> — </span>A quantitative <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> urine level can be obtained to verify buprenorphine use, but can be falsified by adding pieces of buprenorphine tablets to the urine. If tampering is suspected, then the urine should be tested for buprenorphine metabolites (eg, norbuprenorphine).</p><p><a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">Buprenorphine</a> levels are not used to guide dosing. </p><p class="headingAnchor" id="H804588133"><span class="h2">Side effects</span><span class="headingEndMark"> — </span>Common side effects include chills, fever, abdominal pain, vasodilation, withdrawal, constipation, nausea, vomiting, diarrhea, insomnia, and anxiety. Like other opioids, <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> may cause respiratory depression, particularly when taken with benzodiazepines or other central nervous system depressants [<a href="#rid139">139</a>]. Acute hepatotoxicity has been reported rarely in patients with OUD treated with buprenorphine.</p><p>Because it is a partial agonist at the mu-opioid receptor, initiation of <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> may lead to withdrawal symptoms in patients with OUD, particularly if it is given within six hours of opioid use [<a href="#rid136">136</a>]. </p><p class="headingAnchor" id="H16284347"><span class="h2">Drug and chemical interactions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">Buprenorphine</a> has fewer drug interactions compared with <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> [<a href="#rid140">140,141</a>]. It does not increase the QT interval to any clinically meaningful degree. A brief synopsis of drug interactions follows; more information is available in the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p class="bulletIndent1"><span class="glyph">●</span>Because it is primarily metabolized by the cytochrome P450 enzyme pathway, close monitoring for withdrawal symptoms is recommended for buprenorphine-maintained patients who are started on CYP3A4 inducers (eg, rifampicin, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>), as dose increases may be required. In contrast, dose reduction may be required if CYP3A4 inhibitors (eg, <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a>, gestodene, <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, and some HIV protease inhibitors) are used concomitantly with <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although there may be a theoretical risk of additive central nervous system and/or cardiorespiratory depressive effects with combined use of opioids and high doses of <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">magnesium sulfate</a> (as used for prevention of eclampsia or for neuroprotection), we have neither observed nor read case reports of such adverse drug interactions and do not alter dosing in patients receiving both drugs during labor. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Benzodiazepines, and other sedative hypnotics, may act synergistically with <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a>. As with <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, co-prescribing buprenorphine with benzodiazepines may increase the risk of respiratory difficulties, coma, or death [<a href="#rid142">142</a>]; carefully tapering benzodiazepines is recommended. </p><p></p><p class="headingAnchor" id="H16284264"><span class="h2">Intrapartum and postpartum buprenorphine dosing</span><span class="headingEndMark"> — </span>Patients admitted in labor or before scheduled cesarean birth should continue to receive their full daily <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> dose. Discontinuation exposes the mother and fetus to the potential risks of withdrawal. Furthermore, discontinuation can precipitate withdrawal symptoms during reintroduction of buprenorphine in postpartum patients receiving opioid analgesics for pain control [<a href="#rid143">143</a>].</p><p><a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">Buprenorphine</a> maintenance therapy is usually dosed once daily; patients taking split doses should continue taking their buprenorphine as prescribed. Intrapartum, some clinicians divide the daily buprenorphine dose into three doses administered every eight hours. (See  <a class="medical medical_review" href="/z/d/html/130304.html" rel="external">"Obstetric anesthesia for patients with opioid use disorder or opioid tolerance", section on 'Continue baseline opioid'</a>.)</p><p>Doses of <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> and other prescribed opioids should be verified when possible, especially on admission to labor and delivery. Verification can be accomplished by querying the prescription monitoring program database; however, when dose verification is not possible, such as in an emergency, the daily opioid dose reported by the patient can be given in two to four divided doses while monitoring for sedation and respiratory depression [<a href="#rid144">144</a>]. This approach may also be useful when there is concern about whether the patient is taking their entire prescribed dose [<a href="#rid144">144</a>].</p><p>If the <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> dose was increased during pregnancy, the need to continue this increased dose should be assessed postpartum. Dose adjustments may also be needed in the postpartum period. Overall, during the first year after delivery, one study reported that dose increases were relatively common: zero to four months, 45.3 percent; four to eight months, 33.3 percent; 8 to 12 months, 33.3 percent [<a href="#rid145">145</a>]. </p><p>Continuing MOUD after discharge is important to support abstinence from other opioids and retention in treatment of OUD. (See  <a class="medical medical_review" href="/z/d/html/4790.html" rel="external">"Opioid use disorder: Overview of treatment during pregnancy", section on 'Continue MOUD'</a>.)</p><p class="headingAnchor" id="H2970313306"><span class="h2">Breastfeeding</span><span class="headingEndMark"> — </span>Several guidelines from national organizations have considered use of <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> pharmacotherapy compatible with breastfeeding [<a href="#rid23">23,70,146-148</a>]. The drug's poor bioavailability when taken orally means it is unlikely that significant absorption will occur from ingestion of breast milk. Based on data from a few small series, a breastfed infant would receive &lt;1 percent of the maternal weight-adjusted dose [<a href="#rid148">148</a>]. The small amounts of buprenorphine in human milk are unlikely to have short-term negative effects on the developing infant [<a href="#rid149">149</a>]. However, breastfed infants should be monitored for respiratory difficulty, sedation, appropriate feeding, and attainment of developmental milestones, especially in younger, exclusively breastfed infants [<a href="#rid70">70,148</a>]. </p><p>Pregnant patients taking the combination <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> and <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> can be encouraged to breastfeed; although no human safety data are available, neonatal effects are unlikely based upon the limited bioavailability of naloxone [<a href="#rid150">150</a>]. (See <a class="local">'Use of combined buprenorphine and naloxone formulation'</a> below.)</p><p class="headingAnchor" id="H2967381607"><span class="h3">Weaning</span><span class="headingEndMark"> — </span>A single case of infant withdrawal symptoms after sudden cessation of breastfeeding has been reported [<a href="#rid151">151</a>]. Despite the low risk, abrupt cessation of breastfeeding is not recommended [<a href="#rid152">152</a>]. Patients who wish to discontinue breastfeeding are advised to gradually wean the infant from breast milk over a period of two weeks. (See  <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes", section on 'Deciding on method'</a>.)</p><p class="headingAnchor" id="H1612398467"><span class="h2">Pregnancy outcome</span><span class="headingEndMark"> — </span>There is ongoing debate about whether intrauterine exposure to <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> or buprenorphine and <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> results in long-lasting effects for the infant. The available data, discussed below, are generally reassuring. However, studies assessing the impact of buprenorphine on pregnancy outcomes are limited by a multitude of factors, including concomitant exposures to medications and illicit drugs, comorbidities, nutritional factors, and sociodemographic factors, which may confound any association between buprenorphine and adverse pregnancy outcomes.</p><p>According to the Substance Abuse and Mental Health Services Administration, the benefits of pharmacotherapy for OUD during pregnancy outweigh the risks of untreated OUD [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H3746975379"><span class="h3">Neonatal abstinence syndrome</span><span class="headingEndMark"> — </span>Interest in <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> as an alternative to <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> stems from data showing a lower rate of neonatal withdrawal (neonatal abstinence syndrome [NAS]), which has been attributed to its lower bioavailability, lower transplacental passage, and greater affinity to binding to the mu-opioid receptor but with less intrinsic activity than methadone [<a href="#rid118">118,120</a>].</p><p>Data regarding the relationship between the maternal dose of <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> and need for treatment of NAS remain conflicting [<a href="#rid153">153-155</a>]. Quantification of buprenorphine in meconium samples of 10 infants born to buprenorphine-treated patients demonstrated that neither cumulative nor total third-trimester buprenorphine exposure predicted meconium concentrations or infant outcomes [<a href="#rid156">156</a>]. However, there was a possible relationship between meconium buprenorphine concentrations and the onset of NAS. </p><p>In a study with 41 participants entering treatment at a specialized treatment program for pregnant individuals, both maternal <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> dose and prenatal polysubstance exposure to illicit substance use/licit substance misuse were independently associated with NAS expression [<a href="#rid154">154</a>]. Polysubstance exposure was associated with more severe NAS expression after controlling for the effects of buprenorphine dose, but unlike with <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, severity was not related to either cigarette or selective serotonin reuptake inhibitor use. </p><p class="headingAnchor" id="H3706112792"><span class="h3">Risk of congenital anomalies</span><span class="headingEndMark"> — </span>Studies of <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> use in pregnancy have not demonstrated an increased risk of congenital anomalies [<a href="#rid157">157</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>A 2016 systematic review including one randomized trial (131 neonates) and four observational studies (933 neonates) comparing <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> versus <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> treatment of pregnant patients with OUD found no significant difference in risk of congenital anomalies between the two treatments, and the overall risk of anomalies was similar to that in the general obstetric population [<a href="#rid78">78</a>]. These data, although reassuring, are insufficient to determine whether either drug is associated with an increased risk of congenital anomalies. Most of the included studies had a medium to high risk of bias, poorly characterized reported defects, failed to describe relevant confounders (maternal use of nonprescription opioids and other substance use, alcohol, and cigarettes; poor maternal nutrition; increased prevalence of maternal infection) or provide adequate details about timing of exposure, and may have missed anomalies not previously known or immediately apparent at birth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study restricted to analysis of congenital anomalies among pregnancies exposed to <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> in the first trimester reported an 8.4 percent rate of anomalies (prevalence ratio compared with no opioid use in pregnancy 2.0, 95% CI 1.2-3.2) [<a href="#rid158">158</a>]. </p><p></p><p>Although concerns about the effects of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> on the developing visual system have been raised (see <a class="local">'Risk of other fetal and neonatal effects'</a> above), <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> exposure does not appear to confer this risk [<a href="#rid90">90</a>]. There are no data on the effect on the thyroid in humans.</p><p class="headingAnchor" id="H2256939427"><span class="h3">Birth weight</span><span class="headingEndMark"> — </span>Compared with neonates born to nonopioid-dependent patients, neonates exposed in utero to <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> appear to have lower birth weight; however, the effect on head circumference is less clear, with at least one study reporting no reduction in head circumference [<a href="#rid159">159</a>]. Several observational and randomized studies have demonstrated longer gestation, increased birth weight, and larger head circumference in buprenorphine-exposed versus methadone-exposed pregnancies [<a href="#rid78">78,160</a>].</p><p>These are interrelated variables (ie, larger head circumference may be the result of later gestational age at birth), and most studies were limited in their ability to control for confounding factors (eg, prior obstetric history, smoking, etc). Other large studies have not consistently confirmed a difference in these outcomes [<a href="#rid159">159,161,162</a>]. </p><p class="headingAnchor" id="H3000750054"><span class="h3">Risk of adverse long-term consequences</span><span class="headingEndMark"> — </span>There are few long-term neurodevelopmental studies of buprenorphine-exposed fetuses [<a href="#rid162">162-166</a>]. The lack of such studies documenting absence of adverse long-term effects should be discussed with patients contemplating <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> maintenance therapy [<a href="#rid23">23</a>]. Most of the available data come from small retrospective series lacking comparisons with existing treatments, untreated patients with OUD, or normal controls; therefore, the ability to address confounding factors is limited (especially exposure to other substances). Research on long-term neurodevelopmental outcome is further limited by high rates of attrition, heterogeneity in the methods of assessment, and length of follow-up.</p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive and motor development.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One study (n = 21 children) reported lower scores on cognitive and language scales at three years of age in children exposed prenatally to maternal <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> use compared with nonexposed controls [<a href="#rid163">163</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A longitudinal study, which included 73 children evaluated at 24 months (n = 24 <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> exposed, n = 19 <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> exposed, n = 30 nonexposed controls) found no differences between groups in neurologic development or temperament during the first two years of life [<a href="#rid162">162</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective study observed that in utero exposure to maternal <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> dose &gt;100 mg/day was associated with a reduction in infant head circumference compared with <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> or lower dose methadone; it also appeared to have a negative impact on motor skill development during early infancy [<a href="#rid167">167</a>], but others have not confirmed this finding [<a href="#rid168">168</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Brain imaging and EEG.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A small series reported no structural or signal abnormalities on neonatal magnetic resonance imaging in seven infants exposed in utero to <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> pharmacotherapy [<a href="#rid164">164</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A small series reported no abnormalities on electroencephalography (n = 9 neonates) or cranial ultrasound (n = 10 neonates) born to patients on <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> pharmacotherapy [<a href="#rid165">165</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Visual development</strong> – Differences in visual development typically have not been noted after in utero <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> exposure. An increase in strabismus was observed in one study (odds ratio [OR] 3.54; 95% CI 1.26-9.94); however, cigarette use was also strongly associated with strabismus and reduced visual acuity [<a href="#rid169">169</a>]. Further study is needed to determine whether the impact on visual development is due to buprenorphine or other co-occurring exposures. </p><p></p><p class="headingAnchor" id="H1873183280"><span class="h1">SPECIAL ISSUES</span></p><p class="headingAnchor" id="H3182069621"><span class="h2">Preconception pharmacotherapy</span><span class="headingEndMark"> — </span>Conceiving while on <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> has been associated with better drug treatment outcomes compared with individuals who initiate methadone during pregnancy [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H2463607739"><span class="h2">Switching from methadone to buprenorphine therapy</span><span class="headingEndMark"> — </span>We agree with the American College of Obstetricians and Gynecologists' recommendation against transitioning patients from <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> to <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> before or during pregnancy [<a href="#rid23">23</a>]. If a patient desires to switch, this should be managed by clinicians with appropriate expertise and preferably prior to conception and following an established protocol [<a href="#rid170">170</a>].</p><p>There is no compelling reason to switch patients already on <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> to <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> either before or during pregnancy. Transition from methadone to buprenorphine introduces the possibility for destabilization [<a href="#rid119">119,171</a>]. Transfer from methadone or other long-acting opioids can induce withdrawal symptoms and cause transient dysphoria, although transfer from short-acting opioids appears to be safe [<a href="#rid172">172</a>].</p><p class="headingAnchor" id="H4174274541"><span class="h2">Switching from buprenorphine to methadone therapy</span><span class="headingEndMark"> — </span>There is no compelling reason to switch patients from <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> to <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> who are stable on treatment and who are trying to conceive or are pregnant. According to the World Health Organization guidelines for pharmacologic treatment of opioid dependence: If patients are being successfully treated with buprenorphine, then the benefit of staying with a treatment that is working should be taken into consideration [<a href="#rid173">173</a>]. However, continued opioid withdrawal symptoms or opioid craving/recidivism may suggest a poor response to buprenorphine. In these patients, switching from buprenorphine to methadone may be reasonable.</p><p class="headingAnchor" id="H2926448029"><span class="h2">Use of combined buprenorphine and naloxone formulation</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">Buprenorphine</a> is also available in combination with <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> in a 4:1 ratio. The naloxone combination product is intended to deter intravenous abuse of the sublingual formulation because crushing and injecting the combination formulation causes withdrawal symptoms, which do not occur when the tablet or filmstrip is taken orally or sublingually [<a href="#rid174">174</a>]. However, actual deterrence has not been proven. (See  <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Transmucosal formulations'</a>.)</p><p><a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">Buprenorphine</a> and <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> has been the predominant formulation used in the United States because of the perceived benefits of reduced diversion and misuse and limited access to alternative agents in some areas. The available experience with buprenorphine and naloxone use during pregnancy has been reassuring. A few small studies reported no significant differences in maternal or neonatal outcomes compared with use of buprenorphine alone or <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, but these studies are limited by small sample size and lack of control for confounders such as exposure to other drugs. In a meta-analysis of studies of pregnant patients undergoing treatment for OUD, which included a total of 291 pregnant patients treated with buprenorphine and naloxone, there was no difference in obstetrical or neonatal outcomes between those treated with buprenorphine and naloxone compared with those treated with other medications for OUD [<a href="#rid175">175</a>]. A subgroup analysis showed no difference when treatment with buprenorphine and naloxone was compared with the buprenorphine monoproduct [<a href="#rid176">176</a>]. Long-term follow-up studies of neurodevelopmental outcome are not available. In animal studies naloxone was not associated with an increased risk of congenital anomalies. Naloxone is not detectable in the blood when taken orally and is only detectable at low levels (10 percent) when taken sublingually.</p><p>Previous guidelines recommended use of the <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> monoproduct because of theoretical risks of <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> exposure and withdrawal from misuse, but these risks are not supported by the available data. However, the monoproduct has a higher potential for diversion and misuse, and a higher street value, when compared with the combination product [<a href="#rid23">23</a>]. The American Society of Addiction Medicine (ASAM) issued a focused update to the National Practice Guideline for the Treatment of Opioid Use Disorder, which acknowledged that despite limited data on the use of buprenorphine and naloxone, the consensus of the guideline committee is that the combination product is safe and effective in the pregnant population [<a href="#rid177">177</a>].</p><p>There is no reason to preferentially start pregnant patients on the monoproduct, or switch to the monoproduct in patients who were previously stable on the combination product, although switching was advised in the past. Prescribing decisions should be made with the patient's informed consent after review of the risks and benefits [<a href="#rid132">132</a>]. </p><p class="headingAnchor" id="H4123628881"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113643.html" rel="external">"Society guideline links: Opioid use disorder and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/118165.html" rel="external">"Society guideline links: Substance misuse in pregnancy"</a>.)</p><p class="headingAnchor" id="H1522691"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – The advantages and disadvantages of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> versus <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> pharmacotherapy of opioid use disorder (OUD) are compared in the tables  (<a class="graphic graphic_table graphicRef87713" href="/z/d/graphic/87713.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef118512" href="/z/d/graphic/118512.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/4790.html" rel="external">"Opioid use disorder: Overview of treatment during pregnancy", section on 'Methadone or buprenorphine?'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">Methadone</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pharmacology and adverse effects</strong> – With advancing gestational age, plasma levels of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> progressively decrease and clearance increases so that the half-life falls from an average of 22 to 24 hours in nonpregnant patients to eight hours in pregnancy. Methadone can prolong the QT interval and cause torsades de pointes. (See <a class="local">'Pharmacology'</a> above and <a class="local">'Side effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We begin <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> therapy in an inpatient setting with a single oral dose of methadone 20 to 30 mg for most symptomatic patients. After the initial methadone dose, incremental doses of 5 to 10 mg are administered every three to six hours as needed to treat withdrawal symptoms. After initial stabilization, the patient is discharged, and the methadone dose is increased in 5 to 10 mg increments per week, if indicated, to maintain the lowest dose that controls withdrawal symptoms and minimizes the desire to use additional opioids. In our experience, the average dose is approximately 120 mg. (See <a class="local">'Initial dosing'</a> above and <a class="local">'Maintenance dosing after initial stabilization'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Twice-daily dosing at 12-hour intervals (or rarely, three times daily at eight-hour intervals) results in more sustained plasma levels, fewer withdrawal symptoms, less illicit drug use, and less effect on fetal behavior than a single high <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> dose. However, split dosing is not possible for all patients because it requires that she is a candidate for take-home doses. (See <a class="local">'Role of twice-daily maintenance dosing'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Opioid withdrawal symptoms mimic common discomforts of pregnancy (nausea, vomiting, low back pain), which should be taken into account before increasing the daily <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> dose. (See <a class="local">'Maintenance dosing after initial stabilization'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The patient's usual <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> dose should be continued intrapartum. (See <a class="local">'Intrapartum and postpartum methadone dosing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory monitoring</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Weekly urine drug screens are performed to monitor for continued nonprescription opioid use and prescription medication misuse. (See <a class="local">'Role of urine drug testing'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">Methadone</a> levels are unnecessary in asymptomatic patients. We check a methadone serum trough level in symptomatic patients with a negative urine drug screen who are excessively sedated or symptomatic despite an increase in methadone dose. These patients may benefit from split dosing. (See <a class="local">'When to check methadone levels'</a> above and <a class="local">'Role of twice-daily maintenance dosing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Breastfeeding</strong> – Patients are encouraged to breastfeed. Those who wish to discontinue breastfeeding should be advised to gradually wean the infant from breast milk over a period of two weeks to reduce the risk of neonatal withdrawal. (See <a class="local">'Breastfeeding'</a> above and <a class="local">'Weaning'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">Buprenorphine</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Provider</strong> – In the United States, <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> can be dispensed by any provider with schedule III authority on their DEA registration to prescribe buprenorphine for opioid use disorder if permitted by applicable state law. (See <a class="local">'Provider'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Candidates</strong> – To minimize the risk of buprenorphine-induced withdrawal symptoms, it should only be initiated when a patient shows objective, observable signs of moderate opioid withdrawal  (<a class="graphic graphic_table graphicRef78130" href="/z/d/graphic/78130.html" rel="external">table 3</a>), usually six hours or longer after the last dose of a short-acting opioid, and potentially longer (24 to 48 hours) following the use of long-acting opioids. (See <a class="local">'Initial and maintenance dosing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>There is no reason to preferentially start pregnant patients on the <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> monoproduct or switch to the monoproduct in patients who were previously stable on the buprenorphine and <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> combination formulation, as had been advised in the past. (See <a class="local">'Use of combined buprenorphine and naloxone formulation'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Drug dosing for <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> is similar to that in nonpregnant patients. Standard induction protocols, such as the one described above, can be used. Dose adjustments may be needed with advancing gestational age; the average increase appears to be approximately 3 mg. (See <a class="local">'Initial and maintenance dosing'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The patient's usual <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> dosing should be maintained intrapartum and postpartum. (See <a class="local">'Intrapartum and postpartum buprenorphine dosing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Breastfeeding</strong> – Patients are encouraged to breastfeed. Those who wish to discontinue breastfeeding are advised to gradually wean the infant from breast milk over a period of two weeks to reduce the risk of neonatal withdrawal. (See <a class="local">'Breastfeeding'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Department of Consumer and Industry Services Bureau of Health Systems. Administrative rules for substance abuse service programs. http://www.michigan.gov/documents/mdch/AdminRules_for_SA_Serv_Prog_177504_7.pdf (Accessed on April 12, 2016).</li><li><a class="nounderline abstract_t">Finnegan LP, Hagan T, Kaltenbach KA. Scientific foundation of clinical practice: opiate use in pregnant women. Bull N Y Acad Med 1991; 67:223.</a></li><li><a class="nounderline abstract_t">Miles J, Sugumar K, Macrory F, et al. Methadone-exposed newborn infants: outcome after alterations to a service for mothers and infants. Child Care Health Dev 2007; 33:206.</a></li><li class="breakAll">Substance Abuse and Mental Health Services Administration, United States Department of Health and Human Services. Federal guidelines for opioid treatment programs. 2015. https://store.samhsa.gov/shin/content/PEP15-FEDGUIDEOTP/PEP15-FEDGUIDEOTP.pdf (Accessed on July 26, 2018).</li><li class="breakAll">Methadone Treatment of Opioid Dependence and Potential Differences in Product Effect. https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72675a-eng.php (Accessed on April 01, 2020).</li><li class="breakAll">New South Wales methadone maintenance treatment clinical practice guidelines. State health publication, NSW Health Department; Sydney, 1999.</li><li><a class="nounderline abstract_t">Swift RM, Dudley M, DePetrillo P, et al. Altered methadone pharmacokinetics in pregnancy: implications for dosing. J Subst Abuse 1989; 1:453.</a></li><li><a class="nounderline abstract_t">Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10:113.</a></li><li><a class="nounderline abstract_t">Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol 2005; 192:633.</a></li><li><a class="nounderline abstract_t">Felder C, Uehlinger C, Baumann P, et al. Oral and intravenous methadone use: some clinical and pharmacokinetic aspects. Drug Alcohol Depend 1999; 55:137.</a></li><li class="breakAll">Alcohol and other drug treatment guidelines for pregnant, substance-using women. In: Treatment Improvement Protocol Series 2: Pregnant, Substance-abusing Women, Mitchell JL (Ed), Center for Substance Abuse Treatment, Rockville, MD 1995.</li><li><a class="nounderline abstract_t">Kreek MJ. Methadone disposition during the perinatal period in humans. Pharmacol Biochem Behav 1979; 11 Suppl:7.</a></li><li><a class="nounderline abstract_t">Wolff K, Boys A, Rostami-Hodjegan A, et al. Changes to methadone clearance during pregnancy. Eur J Clin Pharmacol 2005; 61:763.</a></li><li><a class="nounderline abstract_t">Nekhayeva IA, Nanovskaya TN, Deshmukh SV, et al. Bidirectional transfer of methadone across human placenta. Biochem Pharmacol 2005; 69:187.</a></li><li><a class="nounderline abstract_t">Nanovskaya TN, Deshmukh SV, Nekhayeva IA, et al. Methadone metabolism by human placenta. Biochem Pharmacol 2004; 68:583.</a></li><li><a class="nounderline abstract_t">Nanovskaya TN, Nekhayeva IA, Hankins GD, Ahmed MS. Transfer of methadone across the dually perfused preterm human placental lobule. Am J Obstet Gynecol 2008; 198:126.e1.</a></li><li><a class="nounderline abstract_t">Burns L, Mattick RP, Lim K, Wallace C. Methadone in pregnancy: treatment retention and neonatal outcomes. Addiction 2007; 102:264.</a></li><li><a class="nounderline abstract_t">Kandall SR, Albin S, Lowinson J, et al. Differential effects of maternal heroin and methadone use on birthweight. Pediatrics 1976; 58:681.</a></li><li><a class="nounderline abstract_t">Doberczak TM, Thornton JC, Bernstein J, Kandall SR. Impact of maternal drug dependency on birth weight and head circumference of offspring. Am J Dis Child 1987; 141:1163.</a></li><li><a class="nounderline abstract_t">Guan Q, Sproule BA, Vigod SN, et al. Impact of timing of methadone initiation on perinatal outcomes following delivery among pregnant women on methadone maintenance therapy in Ontario. Addiction 2019; 114:268.</a></li><li><a class="nounderline abstract_t">Jarlenski M, Chen Q, Gao A, et al. Association of Duration of Methadone or Buprenorphine Use During Pregnancy With Risk of Nonfatal Drug Overdose Among Pregnant Persons With Opioid Use Disorder in the US. JAMA Netw Open 2022; 5:e227964.</a></li><li class="breakAll">Medications development for the treatment of pregnant addicts and their infants. National Institutes of Drug Abuse, Monograph 149, 1995. www.nida.nih.gov/pdf/monographs/download149.html (Accessed on March 18, 2009).</li><li><a class="nounderline abstract_t">Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol 2017; 130:e81.</a></li><li><a class="nounderline abstract_t">Dashe JS, Sheffield JS, Olscher DA, et al. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002; 100:1244.</a></li><li><a class="nounderline abstract_t">Dashe JS, Jackson GL, Olscher DA, et al. Opioid detoxification in pregnancy. Obstet Gynecol 1998; 92:854.</a></li><li><a class="nounderline abstract_t">Berghella V, Lim PJ, Hill MK, et al. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol 2003; 189:312.</a></li><li><a class="nounderline abstract_t">Seligman NS, Salva N, Hayes EJ, et al. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol 2008; 199:396.e1.</a></li><li><a class="nounderline abstract_t">Wilbourne P, Wallerstedt C, Dorato V, Curet LB. Clinical management of methadone dependence during pregnancy. J Perinat Neonatal Nurs 2001; 14:26.</a></li><li class="breakAll">Rettig R. Federal regulation of methadone: Table of contents and executive summary. National Academy Press, Washington, DC 1995. www.drugpolicy.org/library/fedregi.cfm#p3 (Accessed on March 18, 2009).</li><li><a class="nounderline abstract_t">McCarthy JJ, Leamon MH, Parr MS, Anania B. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol 2005; 193:606.</a></li><li class="breakAll">Weiner SM. Perinatal Impact of Substance Abuse, Continuing Education Module, March of Dimes Birth Defects Foundation, White Plains 1993.</li><li><a class="nounderline abstract_t">Jones HE, Heil S, O'Grady KE. Comment on: infants of opioid-dependent mothers: neurodevelopment at six months. Early Hum Dev 2015; 91:243.</a></li><li><a class="nounderline abstract_t">Wilder CM, Hosta D, Winhusen T. Association of methadone dose with substance use and treatment retention in pregnant and postpartum women with opioid use disorder. J Subst Abuse Treat 2017; 80:33.</a></li><li><a class="nounderline abstract_t">Badhan RKS, Gittins R. Precision dosing of methadone during pregnancy: A pharmacokinetics virtual clinical trials study. J Subst Abuse Treat 2021; 130:108521.</a></li><li><a class="nounderline abstract_t">Rosenthal EW, Short VL, Cruz Y, et al. Racial inequity in methadone dose at delivery in pregnant women with opioid use disorder. J Subst Abuse Treat 2021; 131:108454.</a></li><li><a class="nounderline abstract_t">DePetrillo PB, Rice JM. Methadone dosing and pregnancy: impact on program compliance. Int J Addict 1995; 30:207.</a></li><li><a class="nounderline abstract_t">Jansson LM, Dipietro JA, Velez M, et al. Maternal methadone dosing schedule and fetal neurobehaviour. J Matern Fetal Neonatal Med 2009; 22:29.</a></li><li><a class="nounderline abstract_t">Wittmann BK, Segal S. A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation. Int J Addict 1991; 26:213.</a></li><li class="breakAll">Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland. Clinical practice guideline: Methadone prescribing and administration in pregnancy. 2015. https://rcpi-live-cdn.s3.amazonaws.com/wp-content/uploads/2016/05/16.-Methadone-Prescribing-and-Administration-in-Pregnancy.pdf (Accessed on July 26, 2018).</li><li class="breakAll">http://pcssnow.org/wp-content/uploads/2015/01/PCSSMAT-Administrative-Medico-Legal-and-Regulatory-Aspects-of-Opioid-Use-Disorder-MAT.pdf (Accessed on July 26, 2018).</li><li><a class="nounderline abstract_t">Jarvis M, Williams J, Hurford M, et al. Appropriate Use of Drug Testing in Clinical Addiction Medicine. J Addict Med 2017; 11:163.</a></li><li class="breakAll">American Society of Addiction Medicine (ASAM). The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine. https://www.asam.org/resources/quality/drug-testing (Accessed on August 26, 2019).</li><li><a class="nounderline abstract_t">ACOG Committee on Health Care for Underserved Women, American Society of Addiction Medicine. ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012; 119:1070. Reaffirmed 2014.</a></li><li><a class="nounderline abstract_t">Arlettaz R, Kashiwagi M, Das-Kundu S, et al. Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources. Acta Obstet Gynecol Scand 2005; 84:145.</a></li><li><a class="nounderline abstract_t">Fajemirokun-Odudeyi O, Sinha C, Tutty S, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol 2006; 126:170.</a></li><li><a class="nounderline abstract_t">McCarthy JJ, Leamon MH, Stenson G, Biles LA. Outcomes of neonates conceived on methadone maintenance therapy. J Subst Abuse Treat 2008; 35:202.</a></li><li><a class="nounderline abstract_t">Johnson K, Greenough A, Gerada C. Maternal drug use and length of neonatal unit stay. Addiction 2003; 98:785.</a></li><li class="breakAll">Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder – Full Document (Including Executive Summary and Parts 1-5). TIP 63: Medications for Opioid Use Disorder – Full Document (Including Executive Summary and Parts 1-5) (Accessed on August 26, 2019).</li><li><a class="nounderline abstract_t">Hallinan R, Ray J, Byrne A, et al. Therapeutic thresholds in methadone maintenance treatment: a receiver operating characteristic analysis. Drug Alcohol Depend 2006; 81:129.</a></li><li><a class="nounderline abstract_t">Drozdick J 3rd, Berghella V, Hill M, Kaltenbach K. Methadone trough levels in pregnancy. Am J Obstet Gynecol 2002; 187:1184.</a></li><li><a class="nounderline abstract_t">Bogen DL, Hanusa BH, Perel JM, et al. Corrected QT Interval and Methadone Dose and Concentrations in Pregnant and Postpartum Women. J Clin Psychiatry 2017; 78:e1013.</a></li><li><a class="nounderline abstract_t">Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet 2003; 42:819.</a></li><li><a class="nounderline abstract_t">Totah RA, Sheffels P, Roberts T, et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008; 108:363.</a></li><li><a class="nounderline abstract_t">Tong TG, Pond SM, Kreek MJ, et al. Phenytoin-induced methadone withdrawal. Ann Intern Med 1981; 94:349.</a></li><li><a class="nounderline abstract_t">Pace CA, Kaminetzky LB, Winter M, et al. Postpartum changes in methadone maintenance dose. J Subst Abuse Treat 2014; 47:229.</a></li><li><a class="nounderline abstract_t">Ward C, Christensen CW. Methadone for Opioid Use Treatment during Pregnancy: Trends in Postpartum Dose Adjustments. AJP Rep 2020; 10:e202.</a></li><li><a class="nounderline abstract_t">Albright B, de la Torre L, Skipper B, et al. Changes in methadone maintenance therapy during and after pregnancy. J Subst Abuse Treat 2011; 41:347.</a></li><li><a class="nounderline abstract_t">Jones HE, Johnson RE, O'Grady KE, et al. Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. J Addict Med 2008; 2:103.</a></li><li><a class="nounderline abstract_t">Jansson LM, Velez M, Harrow C. Methadone maintenance and lactation: a review of the literature and current management guidelines. J Hum Lact 2004; 20:62.</a></li><li><a class="nounderline abstract_t">Academy of Breastfeeding Medicine Protocol Committee, Jansson LM. ABM clinical protocol #21: Guidelines for breastfeeding and the drug-dependent woman. Breastfeed Med 2009; 4:225.</a></li><li><a class="nounderline abstract_t">Lim S, Prasad MR, Samuels P, et al. High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol 2009; 200:70.e1.</a></li><li><a class="nounderline abstract_t">Jansson LM, Choo R, Velez ML, et al. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics 2008; 121:106.</a></li><li><a class="nounderline abstract_t">Abdel-Latif ME, Pinner J, Clews S, et al. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 2006; 117:e1163.</a></li><li><a class="nounderline abstract_t">Ballard JL. Treatment of neonatal abstinence syndrome with breast milk containing methadone. J Perinat Neonatal Nurs 2002; 15:76.</a></li><li><a class="nounderline abstract_t">Liu AJ, Nanan R. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics 2008; 121:869; author reply 869.</a></li><li class="breakAll">Lactmed. Methadone: National Library of Medicine. https://toxnet.nlm.nih.gov (Accessed on June 05, 2018).</li><li><a class="nounderline abstract_t">Wojnar-Horton RE, Kristensen JH, Yapp P, et al. Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. Br J Clin Pharmacol 1997; 44:543.</a></li><li><a class="nounderline abstract_t">Madadi P, Kelly LE, Ross CJ, et al. Forensic Investigation of Methadone Concentrations in Deceased Breastfed Infants. J Forensic Sci 2016; 61:576.</a></li><li class="breakAll">Summary Safety Review - Methadose, Metadol-D (methadone hydrochloride) - Health Canada https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&amp;linkID=SSR00207 (Accessed on August 08, 2018).</li><li><a class="nounderline abstract_t">Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: An update on selected topics. Pediatrics 2013; 132:e796.</a></li><li class="breakAll">Substance Abuse and Mental Health Services Administration. Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants https://store.samhsa.gov/product/Clinical-Guidance-for-Treating-Pregnant-and-Parenting-Women-With-Opioid-Use-Disorder-and-Their-Infants/SMA18-5054 (Accessed on August 26, 2019).</li><li><a class="nounderline abstract_t">Kotelchuck M, Cheng ER, Belanoff C, et al. The Prevalence and Impact of Substance Use Disorder and Treatment on Maternal Obstetric Experiences and Birth Outcomes Among Singleton Deliveries in Massachusetts. Matern Child Health J 2017; 21:893.</a></li><li><a class="nounderline abstract_t">Kocherlakota P. Neonatal abstinence syndrome. Pediatrics 2014; 134:e547.</a></li><li><a class="nounderline abstract_t">Cleary BJ, Donnelly J, Strawbridge J, et al. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 2010; 105:2071.</a></li><li><a class="nounderline abstract_t">Smith J, Lafferty M, Boelig RC, et al. Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome? Am J Perinatol 2022; 39:1138.</a></li><li><a class="nounderline abstract_t">Anand KJ, Campbell-Yeo M. Consequences of prenatal opioid use for newborns. Acta Paediatr 2015; 104:1066.</a></li><li><a class="nounderline abstract_t">Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 2015; 35:650.</a></li><li><a class="nounderline abstract_t">Zedler BK, Mann AL, Kim MM, et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction 2016; 111:2115.</a></li><li class="breakAll">MotherToBaby. Fact Sheet: Methadone. https://mothertobaby.org/fact-sheets/methadone/pdf/ (Accessed on August 27, 2019).</li><li><a class="nounderline abstract_t">Cleary BJ, Donnelly JM, Strawbridge JD, et al. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol 2011; 204:139.e1.</a></li><li><a class="nounderline abstract_t">Cleary B, Loane M, Addor MC, et al. Methadone, Pierre Robin sequence and other congenital anomalies: case-control study. Arch Dis Child Fetal Neonatal Ed 2020; 105:151.</a></li><li class="breakAll">Smith DW. Workshop on Malformations and Morphogenesis. Buford, Georgia 2012.</li><li><a class="nounderline abstract_t">Schulson M, Liu A, Björkman T, et al. Mid-Gestational Enlargement of Fetal Thalami in Women Exposed to Methadone during Pregnancy. Front Surg 2014; 1:28.</a></li><li><a class="nounderline abstract_t">Parikh R, Hussain T, Holder G, et al. Maternal methadone therapy increases QTc interval in newborn infants. Arch Dis Child Fetal Neonatal Ed 2011; 96:F141.</a></li><li><a class="nounderline abstract_t">Monnelly VJ, Hamilton R, Chappell FM, et al. Childhood neurodevelopment after prescription of maintenance methadone for opioid dependency in pregnancy: a systematic review and meta-analysis. Dev Med Child Neurol 2019; 61:750.</a></li><li><a class="nounderline abstract_t">McGlone L, Hamilton R, McCulloch DL, et al. Visual outcome in infants born to drug-misusing mothers prescribed methadone in pregnancy. Br J Ophthalmol 2014; 98:238.</a></li><li><a class="nounderline abstract_t">Spiteri Cornish K, Hrabovsky M, Scott NW, et al. The short- and long-term effects on the visual system of children following exposure to maternal substance misuse in pregnancy. Am J Ophthalmol 2013; 156:190.</a></li><li><a class="nounderline abstract_t">Nita M, Grzybowski A. Smoking and Eye Pathologies. A Systemic Review. Part II. Retina Diseases, Uveitis, Optic Neuropathies, Thyroid-Associated Orbitopathy. Curr Pharm Des 2017; 23:639.</a></li><li><a class="nounderline abstract_t">Torp-Pedersen T, Boyd HA, Poulsen G, et al. In-utero exposure to smoking, alcohol, coffee, and tea and risk of strabismus. Am J Epidemiol 2010; 171:868.</a></li><li><a class="nounderline abstract_t">Whitham JN, Spurrier NJ, Baghurst PA, et al. Visual evoked potential latencies of three-year-old children prenatally exposed to buprenorphine or methadone compared with non-opioid exposed children: The results of a longitudinal study. Neurotoxicol Teratol 2015; 52:17.</a></li><li><a class="nounderline abstract_t">Mozurkewich EL, Rayburn WF. Buprenorphine and methadone for opioid addiction during pregnancy. Obstet Gynecol Clin North Am 2014; 41:241.</a></li><li><a class="nounderline abstract_t">Liu AJ, Sithamparanathan S, Jones MP, et al. Growth restriction in pregnancies of opioid-dependent mothers. Arch Dis Child Fetal Neonatal Ed 2010; 95:F258.</a></li><li><a class="nounderline abstract_t">Lifschitz MH, Wilson GS, Smith EO, Desmond MM. Fetal and postnatal growth of children born to narcotic-dependent women. J Pediatr 1983; 102:686.</a></li><li><a class="nounderline abstract_t">Mactier H, Shipton D, Dryden C, Tappin DM. Reduced fetal growth in methadone-maintained pregnancies is not fully explained by smoking or socio-economic deprivation. Addiction 2014; 109:482.</a></li><li><a class="nounderline abstract_t">Cruz Y, Reyes A, Berghella V, Roman A. 393: Impact of methadone and tobacco exposure on fetal growth. Am J Obstet Gynecol 2019; 220:S268.</a></li><li><a class="nounderline abstract_t">Rajegowda BK, Glass L, Evans HE, et al. Methadone withdrawal in newborn infants. J Pediatr 1972; 81:532.</a></li><li><a class="nounderline abstract_t">Kashiwagi M, Arlettaz R, Lauper U, et al. Methadone maintenance program in a Swiss perinatal center: (I): Management and outcome of 89 pregnancies. Acta Obstet Gynecol Scand 2005; 84:140.</a></li><li><a class="nounderline abstract_t">Kandall SR, Gaines J, Habel L, et al. Relationship of maternal substance abuse to subsequent sudden infant death syndrome in offspring. J Pediatr 1993; 123:120.</a></li><li><a class="nounderline abstract_t">Cohen MC, Morley SR, Coombs RC. Maternal use of methadone and risk of sudden neonatal death. Acta Paediatr 2015; 104:883.</a></li><li><a class="nounderline abstract_t">Alinsky RH, Alexander GC. Opioid use disorder during pregnancy: long-term developmental outcomes. Dev Med Child Neurol 2021; 63:1016.</a></li><li><a class="nounderline abstract_t">Wouldes TA, Woodward LJ. Neurobehavior of newborn infants exposed prenatally to methadone and identification of a neurobehavioral profile linked to poorer neurodevelopmental outcomes at age 24 months. PLoS One 2020; 15:e0240905.</a></li><li><a class="nounderline abstract_t">Levine TA, Davie-Gray A, Kim HM, et al. Prenatal methadone exposure and child developmental outcomes in 2-year-old children. Dev Med Child Neurol 2021; 63:1114.</a></li><li><a class="nounderline abstract_t">Monnelly VJ, Anblagan D, Quigley A, et al. Prenatal methadone exposure is associated with altered neonatal brain development. Neuroimage Clin 2018; 18:9.</a></li><li><a class="nounderline abstract_t">Caritis SN, Panigrahy A. Opioids affect the fetal brain: reframing the detoxification debate. Am J Obstet Gynecol 2019; 221:602.</a></li><li><a class="nounderline abstract_t">Skurtveit S, Nechanská B, Handal M, et al. Hospitalization of children after prenatal exposure to opioid maintenance therapy during pregnancy: a national registry study from the Czech Republic. Addiction 2019; 114:1225.</a></li><li class="breakAll">Substance Abuse anda Mental Health Services Administration. Removal of DATA Waiver (X-Waiver) Requirement. https://www.samhsa.gov/medications-substance-use-disorders/removal-data-waiver-requirement (Accessed on February 07, 2023).</li><li><a class="nounderline abstract_t">Patrick SW, Richards MR, Dupont WD, et al. Association of Pregnancy and Insurance Status With Treatment Access for Opioid Use Disorder. JAMA Netw Open 2020; 3:e2013456.</a></li><li><a class="nounderline abstract_t">Jansson LM, Svikis D, Lee J, et al. Pregnancy and addiction. A comprehensive care model. J Subst Abuse Treat 1996; 13:321.</a></li><li><a class="nounderline abstract_t">Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55:569.</a></li><li><a class="nounderline abstract_t">Bullingham RE, McQuay HJ, Porter EJ, et al. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Clin Pharmacol 1982; 13:665.</a></li><li><a class="nounderline abstract_t">Kuhlman JJ Jr, Lalani S, Magluilo J Jr, et al. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 1996; 20:369.</a></li><li><a class="nounderline abstract_t">Concheiro M, Jones HE, Johnson RE, et al. Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women. Ther Drug Monit 2011; 33:619.</a></li><li><a class="nounderline abstract_t">Kacinko SL, Jones HE, Johnson RE, et al. Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment. Clin Chem 2009; 55:1177.</a></li><li><a class="nounderline abstract_t">Nanovskaya T, Deshmukh S, Brooks M, Ahmed MS. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther 2002; 300:26.</a></li><li><a class="nounderline abstract_t">Bartu AE, Ilett KF, Hackett LP, et al. Buprenorphine exposure in infants of opioid-dependent mothers at birth. Aust N Z J Obstet Gynaecol 2012; 52:342.</a></li><li><a class="nounderline abstract_t">Fokina VM, Patrikeeva SL, Zharikova OL, et al. Transplacental transfer and metabolism of buprenorphine in preterm human placenta. Am J Perinatol 2011; 28:25.</a></li><li><a class="nounderline abstract_t">Caritis SN, Bastian JR, Zhang H, et al. An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy. Am J Obstet Gynecol 2017; 217:459.e1.</a></li><li><a class="nounderline abstract_t">Young JL, Martin PR. Treatment of opioid dependence in the setting of pregnancy. Psychiatr Clin North Am 2012; 35:441.</a></li><li><a class="nounderline abstract_t">Jones HE, Martin PR, Heil SH, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 2008; 35:245.</a></li><li><a class="nounderline abstract_t">Jones HE, Heil SH, Baewert A, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 2012; 107 Suppl 1:5.</a></li><li><a class="nounderline abstract_t">Soeffing JM, Martin LD, Fingerhood MI, et al. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat 2009; 37:426.</a></li><li><a class="nounderline abstract_t">Bastian JR, Chen H, Zhang H, et al. Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy. Am J Obstet Gynecol 2017; 216:64.e1.</a></li><li><a class="nounderline abstract_t">Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Microinduction of Buprenorphine/Naloxone: A Review of the Literature. Am J Addict 2021; 30:305.</a></li><li><a class="nounderline abstract_t">Baumgartner K, Salmo E, Liss D, et al. Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study. Clin Toxicol (Phila) 2022; 60:688.</a></li><li><a class="nounderline abstract_t">Irwin M, Petersen KS, Smith MA. Rapid Buprenorphine Induction for Cancer Pain in Pregnancy. J Palliat Med 2021; 24:1257.</a></li><li><a class="nounderline abstract_t">2021 Poster Abstracts. J Addict Med 2021; 15:E1.</a></li><li><a class="nounderline abstract_t">Coish R, Hardial J. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report. J Addict Med 2023; 17:114.</a></li><li><a class="nounderline abstract_t">Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79:1.</a></li><li><a class="nounderline abstract_t">Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006; 101:275.</a></li><li><a class="nounderline abstract_t">Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363:2320.</a></li><li><a class="nounderline abstract_t">Zhang H, Bastian JR, Zhao W, et al. Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine. Ther Drug Monit 2020; 42:264.</a></li><li class="breakAll">Substance Abuse and Mental Health Services Administration. Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants. HHS Publication No. (SMA) 18-5054. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018. </li><li><a class="nounderline abstract_t">Bryson EO, Lipson S, Gevirtz C. Anesthesia for patients on buprenorphine. Anesthesiol Clin 2010; 28:611.</a></li><li><a class="nounderline abstract_t">Gevirtz C, Frost EA, Bryson EO. Perioperative implications of buprenorphine maintenance treatment for opioid addiction. Int Anesthesiol Clin 2011; 49:147.</a></li><li class="breakAll">Saxon, AJ. PCSS MAT Training. Providers' clinical support system for medication assisted treatment. https://pcssnow.org/wp-content/uploads/2014/03/PCSS-MATGuidanceMonitoringLiverFunctionTests-and-HepatitisInBupPatients.Saxon_.pdf (Accessed on June 05, 2018).</li><li class="breakAll">RB Pharmaceuticals Limited. Summary of Product Characteristics- Subutex 0.4 mg, 2 mg and 8 mg Sublingual Tablets. www.medicines.ie. (Accessed on January 07, 2013).</li><li class="breakAll">UK data sheet. http://www.medicines.org.uk/emcmobile/medicine/26614/spc#POSOLOGY. (Accessed on March 04, 2013).</li><li class="breakAll">Irish data sheet. http://www.medicines.ie/document.aspx?documentId=1658#POSOLOGY. (Accessed on March 04, 2013).</li><li class="breakAll">Martindale: The Complete Drug Reference. [Online] London: Pharmaceutical Press. http://www.medicinescomplete.com.proxy.library.rcsi.ie/ (Accessed on December 11, 2012).</li><li><a class="nounderline abstract_t">McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010; 19:4.</a></li><li><a class="nounderline abstract_t">McCance-Katz EF, Mandell TW. Drug interactions of clinical importance with methadone and buprenorphine. Am J Addict 2010; 19:2.</a></li><li class="breakAll">US Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, MD, on the agency’s continued efforts to promote the safe adoption of medication-assisted treatment for opioid addiction. 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576752.htm (Accessed on July 26, 2018).</li><li><a class="nounderline abstract_t">Jones HE, Deppen K, Hudak ML, et al. Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers. Am J Obstet Gynecol 2014; 210:302.</a></li><li><a class="nounderline abstract_t">Huxtable CA, Roberts LJ, Somogyi AA, MacIntyre PE. Acute pain management in opioid-tolerant patients: a growing challenge. Anaesth Intensive Care 2011; 39:804.</a></li><li><a class="nounderline abstract_t">Martin CE, Shadowen C, Thakkar B, et al. Buprenorphine dosing for the treatment of opioid use disorder through pregnancy and postpartum. Curr Treat Options Psychiatry 2020; 7:375.</a></li><li><a class="nounderline abstract_t">Wong S, Ordean A, Kahan M, Society of Obstetricians and Gynecologists of Canada. SOGC clinical practice guidelines: Substance use in pregnancy: no. 256, April 2011. Int J Gynaecol Obstet 2011; 114:190.</a></li><li class="breakAll">Center for Substance Abuse Treatment (CSAT). Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. DHHS Publication No. (SMA) 04-3939. Rockville (MD): Substance Abuse and Mental Health Services Administration (SAMHSA), 2004.</li><li class="breakAll">Lactmed. Buprenorphine: National Library of Medicine. http://toxnet.nlm.nih.gov (Accessed on January 23, 2013).</li><li><a class="nounderline abstract_t">Reece-Stremtan S, Marinelli KA. ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. Breastfeed Med 2015; 10:135.</a></li><li><a class="nounderline abstract_t">Alto WA, O'Connor AB. Management of women treated with buprenorphine during pregnancy. Am J Obstet Gynecol 2011; 205:302.</a></li><li><a class="nounderline abstract_t">Elladki H, Thill P. Buprenorphine withdrawal in an infant after cessation of breastfeeding: A case report and review of the literature. Pharmacotherapy 2011; 31:435e.</a></li><li class="breakAll">MotherToBaby. Buprenorphine. https://mothertobaby.org/fact-sheets/buprenorphine/ (Accessed on June 05, 2018).</li><li><a class="nounderline abstract_t">O'Connor AB, O'Brien L, Alto WA. Maternal Buprenorphine Dose at Delivery and Its Relationship to Neonatal Outcomes. Eur Addict Res 2016; 22:127.</a></li><li><a class="nounderline abstract_t">Jansson LM, Velez ML, McConnell K, et al. Maternal buprenorphine treatment and infant outcome. Drug Alcohol Depend 2017; 180:56.</a></li><li><a class="nounderline abstract_t">Lappen JR, Stark S, Bailit JL, Gibson KS. Delivery dose of methadone, but not buprenorphine, is associated with the risk and severity of neonatal opiate withdrawal syndrome. Am J Obstet Gynecol MFM 2020; 2:100075.</a></li><li><a class="nounderline abstract_t">Kacinko SL, Jones HE, Johnson RE, et al. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther 2008; 84:604.</a></li><li class="breakAll">MotherToBaby. Fact sheet: Buprenorphine. https://mothertobaby.org/fact-sheets/buprenorphine/pdf/ (Accessed on August 27, 2019).</li><li><a class="nounderline abstract_t">Nørgaard M, Nielsson MS, Heide-Jørgensen U. Birth and Neonatal Outcomes Following Opioid Use in Pregnancy: A Danish Population-Based Study. Subst Abuse 2015; 9:5.</a></li><li><a class="nounderline abstract_t">O'Connor A, O'Brien L, Watson L. Implications of perinatal buprenorphine exposure on infant head circumference at birth. J Matern Fetal Neonatal Med 2021; 34:318.</a></li><li><a class="nounderline abstract_t">Brogly SB, Saia KA, Walley AY, et al. Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am J Epidemiol 2014; 180:673.</a></li><li><a class="nounderline abstract_t">Lejeune C, Simmat-Durand L, Gourarier L, et al. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006; 82:250.</a></li><li class="breakAll">Whitham J, Prenatal exposure to buprenorphine or methadone 2012.</li><li><a class="nounderline abstract_t">Salo S, Kivisto K, Korja R, et al. Emotional Availability, Parental Self-Efficacy Beliefs, and Child Development in Caregiver-Child Relationships with Buprenorphine-Exposed 3-year-olds. Parent Sci Pract 2009; 9:244.</a></li><li><a class="nounderline abstract_t">Kahila H, Kivitie-Kallio S, Halmesmäki E, et al. Brain magnetic resonance imaging of infants exposed prenatally to buprenorphine. Acta Radiol 2007; 48:228.</a></li><li><a class="nounderline abstract_t">Kayemba-Kay's S, Laclyde JP. Buprenorphine withdrawal syndrome in newborns: a report of 13 cases. Addiction 2003; 98:1599.</a></li><li><a class="nounderline abstract_t">Kaltenbach K, O'Grady KE, Heil SH, et al. Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes. Drug Alcohol Depend 2018; 185:40.</a></li><li><a class="nounderline abstract_t">Bier JB, Finger AS, Bier BA, et al. Growth and developmental outcome of infants with in-utero exposure to methadone vs buprenorphine. J Perinatol 2015; 35:656.</a></li><li><a class="nounderline abstract_t">Humbarger O, Galanto D, Saia K, et al. Childhood health and development in cohort of Infants exposed prenatally to methadone or buprenorphine. J Addict Res Ther 2016; 7:1.</a></li><li><a class="nounderline abstract_t">O'Connor AB, O'Brien LM, Rifai Taunia, et al. Ocular disorders in children exposed in utero to buprenorphine. Journal of Substance Use 2021; 26:664.</a></li><li><a class="nounderline abstract_t">Johnson S, Martin PR. Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy. Am J Drug Alcohol Abuse 2018; 44:310.</a></li><li><a class="nounderline abstract_t">Bruce RD, Moody DE, Altice FL, et al. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol 2013; 6:249.</a></li><li><a class="nounderline abstract_t">Jones HE, Johnson RE, Jasinski DR, Milio L. Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone. Drug Alcohol Depend 2005; 78:33.</a></li><li class="breakAll">World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence 2009.</li><li><a class="nounderline abstract_t">Newman RG, Gevertz SG. Comment on "a comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes". Subst Abuse 2013; 7:107.</a></li><li><a class="nounderline abstract_t">Link HM, Jones H, Miller L, et al. Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis. Am J Obstet Gynecol MFM 2020; 2:100179.</a></li><li><a class="nounderline abstract_t">Link HM, Jones HE, Miller LA, et al. Buprenorphine-naloxone use in pregnancy: a subgroup analysis of medication to treat opioid use disorder. Am J Obstet Gynecol MFM 2021; 3:100369.</a></li><li><a class="nounderline abstract_t">The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med 2020; 14:1.</a></li></ol></div><div id="topicVersionRevision">Topic 87238 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.michigan.gov/documents/mdch/AdminRules_for_SA_Serv_Prog_177504_7.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Department of Consumer and Industry Services Bureau of Health Systems. Administrative rules for substance abuse service programs. http://www.michigan.gov/documents/mdch/AdminRules_for_SA_Serv_Prog_177504_7.pdf (Accessed on April 12, 2016).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1868275" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Scientific foundation of clinical practice: opiate use in pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17291325" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Methadone-exposed newborn infants: outcome after alterations to a service for mothers and infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17291325" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Methadone-exposed newborn infants: outcome after alterations to a service for mothers and infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17291325" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Methadone-exposed newborn infants: outcome after alterations to a service for mothers and infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17291325" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Methadone-exposed newborn infants: outcome after alterations to a service for mothers and infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2485290" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Altered methadone pharmacokinetics in pregnancy: implications for dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19187889" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696014" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10402158" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Oral and intravenous methadone use: some clinical and pharmacokinetic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10402158" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Oral and intravenous methadone use: some clinical and pharmacokinetic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/550136" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Methadone disposition during the perinatal period in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16261362" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Changes to methadone clearance during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15588727" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bidirectional transfer of methadone across human placenta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15242824" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Methadone metabolism by human placenta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166326" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Transfer of methadone across the dually perfused preterm human placental lobule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222281" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Methadone in pregnancy: treatment retention and neonatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/980601" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Differential effects of maternal heroin and methadone use on birthweight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3673965" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Impact of maternal drug dependency on birth weight and head circumference of offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30276907" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Impact of timing of methadone initiation on perinatal outcomes following delivery among pregnant women on methadone maintenance therapy in Ontario.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35438758" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Association of Duration of Methadone or Buprenorphine Use During Pregnancy With Risk of Nonfatal Drug Overdose Among Pregnant Persons With Opioid Use Disorder in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35438758" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Association of Duration of Methadone or Buprenorphine Use During Pregnancy With Risk of Nonfatal Drug Overdose Among Pregnant Persons With Opioid Use Disorder in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28742676" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12468169" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Relationship between maternal methadone dosage and neonatal withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9794682" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Opioid detoxification in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520184" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Maternal methadone dose and neonatal withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18928986" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11930521" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical management of methadone dependence during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11930521" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical management of methadone dependence during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150249" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150249" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25618447" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comment on: infants of opioid-dependent mothers: neurodevelopment at six months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28755770" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Association of methadone dose with substance use and treatment retention in pregnant and postpartum women with opioid use disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34118695" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Precision dosing of methadone during pregnancy: A pharmacokinetics virtual clinical trials study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34098304" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Racial inequity in methadone dose at delivery in pregnant women with opioid use disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7759173" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Methadone dosing and pregnancy: impact on program compliance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19085624" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Maternal methadone dosing schedule and fetal neurobehaviour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1889920" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1889920" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1889920" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28557958" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Appropriate Use of Drug Testing in Clinical Addiction Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28557958" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Appropriate Use of Drug Testing in Clinical Addiction Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22525931" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15683374" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16202501" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pregnancy outcome in women who use opiates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18077124" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Outcomes of neonates conceived on methadone maintenance therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12780366" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Maternal drug use and length of neonatal unit stay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12780366" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Maternal drug use and length of neonatal unit stay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16026938" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Therapeutic thresholds in methadone maintenance treatment: a receiver operating characteristic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12439500" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Methadone trough levels in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28994902" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Corrected QT Interval and Methadone Dose and Concentrations in Pregnant and Postpartum Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12882588" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pharmacokinetic interactions with rifampicin : clinical relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18292673" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Role of CYP2B6 in stereoselective human methadone metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7224382" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Phenytoin-induced methadone withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24953167" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Postpartum changes in methadone maintenance dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33094005" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Methadone for Opioid Use Treatment during Pregnancy: Trends in Postpartum Dose Adjustments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21741197" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Changes in methadone maintenance therapy during and after pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768979" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Dosing adjustments in postpartum patients maintained on buprenorphine or methadone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14974702" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Methadone maintenance and lactation: a review of the literature and current management guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19835481" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : ABM clinical protocol #21: Guidelines for breastfeeding and the drug-dependent woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18976737" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166563" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Methadone maintenance and breastfeeding in the neonatal period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16740817" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11911622" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment of neonatal abstinence syndrome with breast milk containing methadone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18381558" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Methadone maintenance and breastfeeding in the neonatal period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18381558" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Methadone maintenance and breastfeeding in the neonatal period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9431829" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26513313" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Forensic Investigation of Methadone Concentrations in Deceased Breastfed Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26513313" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Forensic Investigation of Methadone Concentrations in Deceased Breastfed Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23979084" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The transfer of drugs and therapeutics into human breast milk: An update on selected topics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23979084" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The transfer of drugs and therapeutics into human breast milk: An update on selected topics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27832443" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The Prevalence and Impact of Substance Use Disorder and Treatment on Maternal Obstetric Experiences and Birth Outcomes Among Singleton Deliveries in Massachusetts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25070299" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Neonatal abstinence syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20840198" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33321531" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26174725" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Consequences of prenatal opioid use for newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25927272" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27223595" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27223595" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21145035" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Methadone and perinatal outcomes: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31229957" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Methadone, Pierre Robin sequence and other congenital anomalies: case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31229957" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Methadone, Pierre Robin sequence and other congenital anomalies: case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25593952" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Mid-Gestational Enlargement of Fetal Thalami in Women Exposed to Methadone during Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21081591" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Maternal methadone therapy increases QTc interval in newborn infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30511742" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Childhood neurodevelopment after prescription of maintenance methadone for opioid dependency in pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24246372" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Visual outcome in infants born to drug-misusing mothers prescribed methadone in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23628351" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The short- and long-term effects on the visual system of children following exposure to maternal substance misuse in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28078992" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Smoking and Eye Pathologies. A Systemic Review. Part II. Retina Diseases, Uveitis, Optic Neuropathies, Thyroid-Associated Orbitopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20338975" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : In-utero exposure to smoking, alcohol, coffee, and tea and risk of strabismus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26432025" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Visual evoked potential latencies of three-year-old children prenatally exposed to buprenorphine or methadone compared with non-opioid exposed children: The results of a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24845488" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Buprenorphine and methadone for opioid addiction during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20388645" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Growth restriction in pregnancies of opioid-dependent mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6842322" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Fetal and postnatal growth of children born to narcotic-dependent women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24321028" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Reduced fetal growth in methadone-maintained pregnancies is not fully explained by smoking or socio-economic deprivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : 393: Impact of methadone and tobacco exposure on fetal growth</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5049821" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Methadone withdrawal in newborn infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15683373" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Methadone maintenance program in a Swiss perinatal center: (I): Management and outcome of 89 pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8320605" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Relationship of maternal substance abuse to subsequent sudden infant death syndrome in offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26011156" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Maternal use of methadone and risk of sudden neonatal death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34181246" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Opioid use disorder during pregnancy: long-term developmental outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33064777" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Neurobehavior of newborn infants exposed prenatally to methadone and identification of a neurobehavioral profile linked to poorer neurodevelopmental outcomes at age 24 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33462809" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Prenatal methadone exposure and child developmental outcomes in 2-year-old children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29326869" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Prenatal methadone exposure is associated with altered neonatal brain development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31323217" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Opioids affect the fetal brain: reframing the detoxification debate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30725515" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Hospitalization of children after prenatal exposure to opioid maintenance therapy during pregnancy: a national registry study from the Czech Republic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30725515" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Hospitalization of children after prenatal exposure to opioid maintenance therapy during pregnancy: a national registry study from the Czech Republic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32797175" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Association of Pregnancy and Insurance Status With Treatment Access for Opioid Use Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9076650" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Pregnancy and addiction. A comprehensive care model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8181201" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Clinical pharmacology of buprenorphine: ceiling effects at high doses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7082534" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8889672" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21860340" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19325013" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11752093" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Transplacental transfer and metabolism of buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22428721" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Buprenorphine exposure in infants of opioid-dependent mothers at birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20607647" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Transplacental transfer and metabolism of buprenorphine in preterm human placenta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28669739" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22640765" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Treatment of opioid dependence in the setting of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18248941" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Treatment of opioid-dependent pregnant women: clinical and research issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23106923" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19553061" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27687214" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33378137" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Microinduction of Buprenorphine/Naloxone: A Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35048759" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33275857" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Rapid Buprenorphine Induction for Cancer Pain in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34609360" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : 2021 Poster Abstracts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35916416" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15943939" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16445556" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21142534" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Neonatal abstinence syndrome after methadone or buprenorphine exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31929398" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31929398" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21074741" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Anesthesia for patients on buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21239911" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Perioperative implications of buprenorphine maintenance treatment for opioid addiction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21239911" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Perioperative implications of buprenorphine maintenance treatment for opioid addiction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21239911" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Perioperative implications of buprenorphine maintenance treatment for opioid addiction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21239911" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Perioperative implications of buprenorphine maintenance treatment for opioid addiction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21239911" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Perioperative implications of buprenorphine maintenance treatment for opioid addiction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21239911" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Perioperative implications of buprenorphine maintenance treatment for opioid addiction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20132117" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20132116" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Drug interactions of clinical importance with methadone and buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20132116" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Drug interactions of clinical importance with methadone and buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24120973" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21970125" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Acute pain management in opioid-tolerant patients: a growing challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33585165" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Buprenorphine dosing for the treatment of opioid use disorder through pregnancy and postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21870360" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : SOGC clinical practice guidelines: Substance use in pregnancy: no. 256, April 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21870360" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : SOGC clinical practice guidelines: Substance use in pregnancy: no. 256, April 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21870360" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : SOGC clinical practice guidelines: Substance use in pregnancy: no. 256, April 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25836677" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21640969" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Management of women treated with buprenorphine during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Buprenorphine withdrawal in an infant after cessation of breastfeeding: A case report and review of the literature</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Buprenorphine withdrawal in an infant after cessation of breastfeeding: A case report and review of the literature</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26491960" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Maternal Buprenorphine Dose at Delivery and Its Relationship to Neonatal Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28869859" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Maternal buprenorphine treatment and infant outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33345989" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Delivery dose of methadone, but not buprenorphine, is associated with the risk and severity of neonatal opiate withdrawal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18701886" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18701886" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26512202" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Birth and Neonatal Outcomes Following Opioid Use in Pregnancy: A Danish Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30905231" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Implications of perinatal buprenorphine exposure on infant head circumference at birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25150272" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16257138" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16257138" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Emotional Availability, Parental Self-Efficacy Beliefs, and Child Development in Caregiver-Child Relationships with Buprenorphine-Exposed 3-year-olds</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17354146" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Brain magnetic resonance imaging of infants exposed prenatally to buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616186" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Buprenorphine withdrawal syndrome in newborns: a report of 13 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29413437" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25836317" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Growth and developmental outcome of infants with in-utero exposure to methadone vs buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Childhood health and development in cohort of Infants exposed prenatally to methadone or buprenorphine</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Ocular disorders in children exposed in utero to buprenorphine</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28829626" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23656339" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15769555" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15769555" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23772177" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Comment on "a comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33345863" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33831585" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Buprenorphine-naloxone use in pregnancy: a subgroup analysis of medication to treat opioid use disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32511106" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
